Prof. dr. J. Schuitemaker

Euler Z, van Gils MJ, Boeser-Nunnink BD, Schuitemaker H, van Manen D, Genome-Wide Association Study on the Development of Cross-Reactive Neutralizing Antibodies in HIV-1 Infected Individuals. PLOS ONE 2013;8 (1):e54684 [PubMed]

Gijsbers EF, van Nuenen AC, Schuitemaker H, Kootstra NA, Gag sequence variation in a human immunodeficiency virus type 1 transmission cluster influences viral replication fitness. J GEN VIROL 2013;94 (Part 2):354-359 [PubMed]

Lodi S, del Amo J, D'Arminio Monforte A, Abgrall S, Sabin C, Morrison C, Furrer H, Muga R, Porter K, Girardi E [Contributors: del Amo J, Meyer L, Bucher HC, Chêne G, Hamouda O, Pillay D, Prins M, Rosinska M, Sabin C, Porter K, Olson A, Coughlin K, Walker S, Babiker A, de Luca A, Fisher M, Muga R, Zangerle R, Kelleher T, Cooper D, Grey P, Finlayson R, Bloch M, Ramacciotti T, Gelgor L, Smith D, Gill J, Lutsar I, Dabis F, Thiebaut R, Masquelier B, Costagliola D, Guiguet M, Boufassa F, Kücherer C, Bartmeyer B, Touloumi G, Pantazis N, Katsarou O, Rezza G, Monforte AdA, Geskus R, van der Helm J, Schuitemaker H, Sannes M, Brubakk O, Kran AMB, Rosinska M, Tor J, de Olalla PG, Cayla J, Moreno S, Monge S, del Romero J, Rickenbach M, Francioli P, Malyuta R, Murphy G, Johnson A, Phillips A, Morrison C, Salata R, Mugerwa R, Chipato T, Amornkul PN, Gilmour J, Kamali A, Giaquinto C, Grarup J, Ledergerber B, Panteleev A, Thorne C, Welch S, Aboulker JP, Albert J, Asandi S, de Wolf F, Gatell J, Koch R, Karpov I, Lundgren J, Møller C, Rockstroh J, Anne AV, Dedes N, Pizzuti D, Vitoria M, Faggion S, Fradette L, Frost R, Schwimmer C, Scott M, Paparizos V, Gargalianos-Kakolyris P, Lazanas M, Pérez-Hoyos S, Kirk O, de Wit S, Rakhmanova A, Dorrucci M, Karita E]] , Risk of tuberculosis following HIV seroconversion in high-income countries. THORAX 2013;68 (3):207-213 [PubMed]

Rotger M, Glass TR, Junier T, Lundgren J, Neaton JD, Poloni ES, van't Wout AB, Lubomirov R, Colombo S, Martinez R, Rauch A, Günthard HF, Neuhaus J, Wentworth D, van Manen D, Gras LA, Schuitemaker H, Albini L, Torti C, Jacobson LP, Li X, Kingsley LA, Carli F, Guaraldi G, Ford ES, Sereti I, Hadigan C, Martinez E, Arnedo M, Egaña-Gorroño L, Gatell JM, Law M, Bendall C, Petoumenos K, Rockstroh J, Wasmuth JC, Kabamba K, Delforge M, de Wit S, Berger F, Mauss S, de Paz Sierra M, Losso M, Belloso WH, Leyes M, Campins A, Mondi A, de Luca A, Bernardino I, Barriuso-Iglesias M, Torrecilla-Rodriguez A, Gonzalez-Garcia J, Arribas JR, Fanti I, Gel S, Puig J, Negredo E, Gutierrez M, Domingo P, Fischer J, Fätkenheuer G, Alonso-Villaverde C, Macken A, Woo J, McGinty T, Mallon P, Mangili A, Skinner S, Wanke CA, Reiss P, Weber R, Bucher HC, Fellay J, Telenti A, Tarr PE, Contribution of genetic background, traditional risk factors and HIV-related factors to coronary artery disease events in HIV-positive persons. CLIN INFECT DIS 2013;ahead of print [PubMed]

Sanders BP, Edo-Matas D, Custers JHHV, Koldijk MH, Klaren V, Turk M, Luitjens A, Bakker WAM, Uytdehaag F, Goudsmit J, Lewis JA, Schuitemaker H, PER.C6(®) cells as a serum-free suspension cell platform for the production of high titer poliovirus: A potential low cost of goods option for world supply of inactivated poliovirus vaccine. VACCINE 2013;31 (5):850-856 [PubMed]

van der Helm J, Geskus R, Sabin C, Meyer L, del Amo J, Chene G, Dorrucci M, Muga R, Porter K, Prins M [Contributors: del Amo J, Meyer L, Bucher HC, Chene G, Hamouda O, Pillay D, Prins M, Rosinska M, Sabin C, Touloumi G, Porter K, Olson A, Coughlin K, Walker S, Babiker A, de Luca A, Fisher M, Muga R, Zangerle R, Kelleher T, Cooper D, Grey P, Finlayson R, Bloch M, Ramacciotti T, Gelgor L, Smith D, Gill J, Lutsar I, Dabis F, Thiebaut R, Masquelier B, Costagliola D, Guiguet M, Vanhems P, Ghosn J, Boufassa F, Kuecherer C, Bartmeyer B, Paparizos V, Gargalianos-Kakolyris P, Lazanas M, Pantazis N, Katsarou O, Dorrucci M, Monforte AdA, Geskus R, van der Helm J, Schuitemaker H, Sannes M, Brubakk O, Kran AMB, Rosinska M, Tor J, de Olalla PG, Cayla J, Moreno S, Monge S, del Romero J, Rickenbach M, Francioli P, Malyuta R, Murphy G, Johnson A, Phillips A, Salata R, Mugerwa R, Chipato T, Amornkul PN, Gilmour J, Kamali A, Karita E, Chaix ML, Rezza G]] , Effect of HCV infection on cause-specific mortality after HIV seroconversion, before and after 1997. GASTROENTEROLOGY 2013;144 (4):751-760.e2 [PubMed]

Barouch DH, Liu J, Li H, Maxfield LF, Abbink P, Lynch DM, Iampietro MJ, Sanmiguel A, Seaman MS, Ferrari G, Forthal DN, Ourmanov I, Hirsch VM, Carville A, Mansfield KG, Stablein D, Pau MG, Schuitemaker H, Sadoff JC, Billings EA, Rao M, Robb ML, Kim JH, Marovich MA, Goudsmit J, Michael NL, Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. NATURE 2012;482 (7383):89-93 [PubMed]

Bol SM, Booiman T, van Manen D, Bunnik EM, van Sighem AI, Sieberer M, Boeser-Nunnink B, de Wolf F, Schuitemaker H, Portegies P, Kootstra NA, van 't Wout AB, Single nucleotide polymorphism in gene encoding transcription factor Prep1 is associated with HIV-1-associated dementia. PLOS ONE 2012;7 (2):e30990 [PubMed]

Edo-Matas D, Rachinger A, Setiawan LC, Boeser-Nunnink BD, van 't Wout AB, Lemey P, Schuitemaker H, The evolution of human immunodeficiency virus type-1 (HIV-1) envelope molecular properties and coreceptor use at all stages of infection in an HIV-1 donor-recipient pair. VIROLOGY 2012;422 (1):70-80 [PubMed]

Euler Z. Humoral immunity in HIV-1 infection. s.l.: s.n.; 2012. 209p. ISBN 97899461820914 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Schuitemaker H; copromotor(s): )

Euler Z, van den Kerkhof TLGM, van Gils MJ, Burger JA, Edo-Matas D, Phung P, Wrin T, Schuitemaker H, Longitudinal analysis of early HIV-1-specific neutralizing activity in an elite neutralizer and in five patients who developed cross-reactive neutralizing activity. J VIROL 2012;86 (4):2045-2055 [PubMed]

Gijsbers EF, Schuitemaker H, Kootstra NA, HIV-1 transmission and viral adaptation to the host. FUTURE VIROL 2012;7 (1):63-71

Grijsen ML, Steingrover R, Wit FWNM, Jurriaans S, Verbon A, Brinkman K, van der Ende ME, Soetekouw R, de Wolf F, Lange JMA, Schuitemaker H, Prins JM [Contributors: Prins JM, Lange JMA, Grijsen ML, Steingrover R, Vermeulen JN, Nievaard M, Slegtenhorst B, Doevelaar H, Koevoets W, Nobel HE, Henderiks A, Pijnappel FJJ, van der Ende ME, Rijinders BJA, Padmos I, van Zonneveld L, Been S, Kauffmann RH, Schippers EF, Korte R, van Ijperen JM, ten Kate RW, Soetekouw R, Hulshoff N, Schoemaker-Ransijn M, Kroon FP, Dorama W, Moons CAM, Verbon A, Lowe SH, Schreij G, van der Geest S, Oude Lashof AM, Schippers J, Bronsveld W, van Twillert G, van Houte D, van Vonderen MGA, Faber S, Rotteveel S, ten Napel CHH, Kootstra GJ, Heins H, Brinkman K, van den Berk GEL, Blok WL, Frissen PHJ, Schouten WEM, Schrijnders L, van Eeden A, Verhagen DWM, Groot M, Brokking W, Mulder JW, van Kasteren MEE, Juttman JR, Kuipers M, Veenstra J, Lettinga KD, Koopmans PP, Bosch M, Hoepelman IM, Mudrikova T, de Koon I]] , No treatment versus 24 or 60 weeks of antiretroviral treatment during primary HIV infection: the randomized Primo-SHM trial. PLOS MED 2012;9 (3):e1001196 [PubMed]

Heyndrickx L, Heath A, Sheik-Khalil E, Alcami J, Bongertz V, Jansson M, Malnati M, Montefiori D, Moog C, Morris L, Osmanov S, Polonis V, Ramaswamy M, Sattentau Q, Tolazzi M, Schuitemaker H, Willems B, Wrin T, Fenyö EM, Scarlatti G, International network for comparison of HIV neutralization assays: the NeutNet report II. PLOS ONE 2012;7 (5):e36438 [PubMed]

Langedijk JPM, Schuitemaker H, A sweet surprise for HIV broadly neutralizing antibodies. NAT MED 2012;18 (11):1616-1617 [PubMed]

Limou S, Delaneau O, van Manen D, An P, Sezgin E, Le Clerc S, Coulonges C, Troyer JL, Veldink JH, van den Berg LH, Spadoni JL, Taing L, Labib T, Montes M, Delfraissy JF, Schachter F, O'Brien SJ, Buchbinder S, van Natta ML, Jabs DA, Froguel P, Schuitemaker H, Winkler CA, Zagury JF, Multicohort genomewide association study reveals a new signal of protection against HIV-1 acquisition. J INFECT DIS 2012;205 (7):1155-1162 [PubMed]

Lynch RM, Tran L, Louder MK, Schmidt SD, Cohen M, DerSimonian R, Euler Z, Gray ES, Abdool Karim S, Kirchherr J, Montefiori DC, Sibeko S, Soderberg K, Tomaras G, Yang ZY, Nabel GJ, Schuitemaker H, Morris L, Haynes BF, Mascola JR, The development of CD4 binding site antibodies during HIV-1 infection. J VIROL 2012;86 (14):7588-7595 [PubMed]

Mouquet H, Scharf L, Euler Z, Liu Y, Eden C, Scheid JF, Halper-Stromberg A, Gnanapragasam PNP, Spencer DIR, Seaman MS, Schuitemaker H, Feizi T, Nussenzweig MC, Bjorkman PJ, Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies. P NATL ACAD SCI USA 2012;109 (47):E3268-E3277 [PubMed]

Pantazis N, Morrison C, Amornkul PN, Lewden C, Salata RA, Minga A, Chipato T, Jaffe H, Lakhi S, Karita E, Porter K, Meyer L, Touloumi G [Contributors: del Amo J, Meyer L, Bucher HC, Chêne G, Hamouda O, Pillay D, Prins M, Rosinska M, Sabin C, Touloumi G, Porter K, Lodi S, Coughlin K, Walker S, Babiker A, de Luca A, Fisher M, Muga R, Zangerle R, Kelleher AD, Cooper DA, Grey P, Finlayson R, Bloch M, Kelleher T, Ramacciotti T, Gelgor L, Cooper D, Smith D, Gill J, Jørgensen LB, Lutsar I, Dabis F, Thiebaut R, Masquelier B, Costagliola D, Guiguet M, Vanhems P, Chaix ML, Ghosn J, Boufassa F, Kücherer C, Bartmeyer B, Pantazis N, Katsarou O, Paparizos V, Gargalianos-Kakolyris P, Lazanas M, Rezza G, Dorrucci M, D'Arminio Monforte A, Geskus R, van der Helm J, Schuitemaker H, Sannes M, Brubakk O, Kran AMB, Rosinska M, Tor J, Garcia de Olalla P, Cayla J, Moreno S, Monge S, del Romero J, Pérez-Hoyos S, Rickenbach M, Francioli P, Malyuta R, Brettle R, Murphy G, Johnson A, Phillips A, Delpech V, Morrison C, Salata R, Mugerwa R, Chipato T, Amornkul P, Giaquinto C, Gibb D, Grarup J, Kirk O, Ledergerber B, Panteleev A, Thorne C, Welch S, Aboulker JP, Albert J, Asandi S, de Wit S, de Wolf F, Gatell J, Karpov I, Lundgren J, Møller C, Rakhmanova A, Rockstroh J, Volny Anne A, Dedes N, Fenton K, Pizzuti D, Vitoria M, Faggion S, Frost R, Fradette L, Schwimmer C, Scott M, Minga A, Lewden C, Abo Y, Dohoun L, Drowa EAY, Bades IB, Kouamé T, N'Dri MJ, Ouattara M, Sidibé A, Afi R, Emieme A, Inwoley A, Toni TdA, Coulibaly A, Bomisso G, Konaté M, Anglaret X, Bazin B, Danel C, Deveau C, Goujard C, Quinty L, Salamon R, Thiébaut R, Rouzioux C, Sinet M, Karita E, Allen S, Anzala O, Bekker LG, Inambao M, Kamali A, Kilembe W, Lakhi S, Latka MH, Sanders E, Mutua G, Mwangome M, Ruzagira E, Twesigye R, Amornkul PN, Cormier E, Fast P, Gilmour J, Krebs M, Price M, Stevens G, Thomson H, Yates S, Kaleebu P, Hunter E, Byamugisha J, Magwali T]] , Differences in HIV natural history among African and non-African seroconverters in Europe and seroconverters in sub-Saharan Africa. PLOS ONE 2012;7 (3):e32369 [PubMed]

Poon AFY, Swenson LC, Bunnik EM, Edo-Matas D, Schuitemaker H, van 't Wout AB, Harrigan PR, Reconstructing the dynamics of HIV evolution within hosts from serial deep sequence data. PLOS COMPUT BIOL 2012;8 (11):e1002753 [PubMed]

Rachinger A, Kootstra NA, Gijsbers EF, van den Kerkhof TLGM, Schuitemaker H, van 't Wout AB, HIV-1 envelope diversity 1 year after seroconversion predicts subsequent disease progression. AIDS 2012;26 (12):1517-1522 [PubMed]

Roy S. Diversity of adenoviruses in humans and in non-human primates. s.l.: s.n.; 2012. 179p. ISBN 9789461820860 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Schuitemaker H; copromotor(s): Wilson JM)

van Manen D, van 't Wout AB, Schuitemaker H, Genome-wide association studies on HIV susceptibility, pathogenesis and pharmacogenomics. RETROVIROLOGY 2012;9 (1):70 [PubMed]

Wang Y, Whittall T, Rahman D, Bunnik EM, Vaughan R, Schøller J, Bergmeier LA, Montefiori D, Singh M, Schuitemaker H, Lehner T, The role of innate APOBEC3G and adaptive AID immune responses in HLA-HIV/SIV immunized SHIV infected macaques. PLOS ONE 2012;7 (4):e34433 [PubMed]

Yang GB, Wang Y, Babaahmady K, Schøller J, Rahman D, Bunnik E, Spallek R, Zong CM, Duan JZ, Qin C, Jiang H, Singh M, Vaughan R, Bergmeier LA, Schuitemaker H, Shao Y, Lehner T, Immunization with recombinant macaque major histocompatibility complex class I and II and human immunodeficiency virus gp140 inhibits simian-human immunodeficiency virus infection in macaques. J GEN VIROL 2012;93 (Part 7):1506-1518 [PubMed]

Zahn R, Gillisen G, Roos A, Koning M, van der Helm E, Spek D, Weijtens M, Grazia Pau M, Radošević K, Weverling GJ, Custers J, Vellinga J, Schuitemaker H, Goudsmit J, Rodríguez A, Ad35 and ad26 vaccine vectors induce potent and cross-reactive antibody and T-cell responses to multiple filovirus species. PLOS ONE 2012;7 (12):e44115 [PubMed]

Zugna D, Geskus RB, de Stavola B, Rosinska M, Bartmeyer B, Boufassa F, Chaix ML, Babiker A, Porter K [Contributors: del Amo J, Meyer L, Bucher HC, Chêne G, Hamouda O, Pillay D, Prins M, Rosinska M, Sabin C, Touloumi G, Porter K, Olson A, Coughlin K, Walker S, Babiker A, de Luca A, Fisher M, Muga R, Zangerle R, Kelleher T, Cooper D, Grey P, Finlayson R, Bloch M, Ramacciotti T, Gelgor L, Smith D, Gill J, Lutsar I, Dabis F, Thiebaut R, Masquelier B, Costagliola D, Guiguet M, Vanhems P, Chaix ML, Ghosn J, Boufassa F, Kücherer C, Bartmeyer B, Paparizos V, Gargalianos-Kakolyris P, Lazanas M, Pantazis N, Katsarou O, Rezza G, Dorrucci M, D'Arminio Monforte A, Geskus R, van der Helm J, Schuitemaker H, Sannes M, Brubakk O, Kran AMB, Rosinska M, Tor J, Garcia de Olalla P, Cayla J, Moreno S, Monge S, del Romero J, Pérez-Hoyos S, Rickenbach M, Francioli P, Malyuta R, Murphy G, Johnson A, Phillips A, Morrison C, Salata R, Mugerwa R, Chipato T, Amornkul PN, Gilmour J, Kamali A, Karita E, Giaquinto C, Gibb D, Grarup J, Kirk O, Ledergerber B, Panteleev A, Thorne C, Welch S, Aboulker JP, Albert J, Asandi S, de Wit S, de Wolf F, Gatell J, Karpov I, Lundgren J, Møller C, Rakhmanova A, Rockstroh J, Anne AV, Dedes N, Fenton K, Pizzuti D, Vitoria M, Ellefson M, Faggion S, Fradette L, Frost R, Schwimmer C, Scott M]] , Time to virological failure, treatment change and interruption for individuals treated within 12 months of HIV seroconversion and in chronic infection. ANTIVIR THER 2012;17 (6):1039-1048 [PubMed]

Bol SM. Host genetic effects on HIV-1 replication in macrophages. s.l.: s.n.; 2011. 200p. ISBN 9789461690944 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Schuitemaker H; copromotor(s): van 't Wout AB)

Bol SM, Booiman T, Bunnik EM, Moerland PD, van Dort K, Strauss JF 3rd, Sieberer M, Schuitemaker H, Kootstra NA, van 't Wout AB, Polymorphism in HIV-1 dependency factor PDE8A affects mRNA level and HIV-1 replication in primary macrophages. VIROLOGY 2011;420 (1):32-42 [PubMed]

Bol SM, Moerland PD, Limou S, van Remmerden Y, Coulonges C, van Manen D, Herbeck JT, Fellay J, Sieberer M, Sietzema JG, van 't Slot R, Martinson J, Zagury JF, Schuitemaker H, van 't Wout AB, Genome-Wide Association Study Identifies Single Nucleotide Polymorphism in DYRK1A Associated with Replication of HIV-1 in Monocyte-Derived Macrophages. PLOS ONE 2011;6 (2):e17190 [PubMed]

Bunnik EM, Swenson LC, Edo-Matas D, Huang W, Dong W, Frantzell A, Petropoulos CJ, Coakley E, Schuitemaker H, Harrigan PR, van 't Wout AB, Detection of inferred CCR5- and CXCR4-using HIV-1 variants and evolutionary intermediates using ultra-deep pyrosequencing. PLOS PATHOG 2011;7 (6):e1002106 [PubMed]

Clerc SL, Coulonges C, Delaneau O, Manen DV, Herbeck JT, Limou S, An P, Martinson JJ, Spadoni JL, Therwath A, Veldink JH, van den Berg LH, Taing L, Labib T, Mellak S, Montes M, Delfraissy JF, Schächter F, Winkler C, Froguel P, Mullins JI, Schuitemaker H, Zagury JF, Screening Low-Frequency SNPS From Genome-Wide Association Study Reveals a New Risk Allele for Progression to AIDS. JAIDS-J ACQ IMM DEF 2011;56 (3):279-284 [PubMed]

Edo-Matas D, Lemey P, Tom JA, Serna-Bolea C, van den Blink AE, van 't Wout AB, Schuitemaker H, Suchard MA, Impact of CCR5delta32 Host Genetic Background and Disease Progression on HIV-1 Intrahost Evolutionary Processes: Efficient Hypothesis Testing through Hierarchical Phylogenetic Models. MOL BIOL EVOL 2011;28 (5):1605-1616 [PubMed]

Edo-Matas D, van Dort KA, Setiawan LC, Schuitemaker H, Kootstra NA, Comparison of in vivo and in vitro evolution of CCR5 to CXCR4 coreceptor use of primary human immunodeficiency virus type 1 variants. VIROLOGY 2011;412 (2):269-277 [PubMed]

Euler Z, Bunnik EM, Burger JA, Boeser-Nunnink BDM, Grijsen ML, Prins JM, Schuitemaker H, Activity of broadly neutralizing antibodies, including PG9, PG16, and VRC01, against recently transmitted subtype B HIV-1 variants from early and late in the epidemic. J VIROL 2011;85 (14):7236-7245 [PubMed]

Jaffe HW, de Stavola BL, Carpenter LM, Porter K, Cox DR [Contributors: del Amo J, Meyer L, Bucher HC, Chêne G, Hamouda O, Pillay D, Prins M, Rosinska M, Sabin C, Touloumi G, Lodi S, Coughlin K, Walker S, Babiker A, de Luca A, Fisher M, Muga R, Zangerle R, Kelleher AD, Cooper DA, Grey P, Finlayson R, Bloch M, Kelleher T, Ramacciotti T, Gelgor L, Cooper D, Gill J, Jørgensen LB, Tartu U, Lutsar I, Dabis F, Thiebaut R, Masquelier B, Costagliola D, Guiguet M, Vanhems P, Chaix ML, Ghosn J, Boufassa F, Kücherer C, Bartmeyer B, Pantazis N, Katsarou O, Rezza G, Dorrucci M, D'Arminio Monforte A, Geskus R, van der Helm J, Schuitemaker H, Sannes M, Brubakk O, Kran AMB, Rosinska M, Tor J, Garcia de Olalla P, Cayla J, Moreno S, Monge S, Pérez-Hoyos S, Rickenbach M, Francioli P, Malyuta R, Brettle R, Johnson A, Phillips A, Delpech V, Morrison C, Salata R, Mugerwa R, Chipato T, Amornkul P]] , Immune reconstitution and risk of Kaposi sarcoma and non-Hodgkin lymphoma in HIV-infected adults. AIDS 2011;25 (11):1395-1403 [PubMed]

Matas DE. Within-host HIV-1 evolution in relation to viral coreceptor use and host environment. s.l.: s.n.; 2011. 254p. ISBN 9789490371562 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Schuitemaker H; copromotor(s): van 't Wout AB)

Mörner A, Jansson M, Bunnik EM, Schøller J, Vaughan R, Wang Y, Montefiori DC, Otting N, Bontrop R, Bergmeier LA, Singh M, Wyatt RT, Schuitemaker H, Biberfeld G, Thorstensson R, Lehner T, Immunization with recombinant HLA classes I and II, HIV-1 gp140, and SIV p27 elicits protection against heterologous SHIV infection in rhesus macaques. J VIROL 2011;85 (13):6442-6452 [PubMed]

Nikolova M, Carriere M, Jenabian MA, Limou S, Younas M, Koek A, Hue S, Seddiki N, Hulin A, Delaneau O, Schuitemaker H, Herbeck JT, Mullins JI, Muhtarova M, Bensussan A, Zagury JF, Lelievre JD, Levy Y, CD39/Adenosine Pathway Is Involved in AIDS Progression. PLOS PATHOG 2011;7 (7):e1002110

Rachinger A, Groeneveld PH, van Assen S, Lemey P, Schuitemaker H, Time-measured phylogenies of gag, pol and env sequence data reveal the direction and time interval of HIV-1 transmission. AIDS 2011;25 (8):1035-1039 [PubMed]

Rachinger A, Manyenga P, Burger JA, Derks van de Ven TLP, Stolte IG, Prins M, van 't Wout AB, Schuitemaker H, Low Incidence of HIV-1 Superinfection Even After Episodes of Unsafe Sexual Behavior of Homosexual Men in the Amsterdam Cohort Studies on HIV Infection and AIDS. J INFECT DIS 2011;203 (11):1621-1628 [PubMed]

Schellens IMM, Navis M, van Deutekom HWM, Boeser-Nunnink B, Berkhout B, Kootstra N, Miedema F, Keşmir C, Schuitemaker H, van Baarle D, Borghans JAM, Loss of HIV-1-derived cytotoxic T lymphocyte epitopes restricted by protective HLA-B alleles during the HIV-1 epidemic. AIDS 2011;25 (14):1691-1700 [PubMed]

Schuitemaker H, van 't Wout AB, Lusso P, Clinical significance of HIV-1 coreceptor usage. J TRANSL MED 2011;9 (Suppl. 1):S5 [PubMed]

Troyer JL, Nelson GW, Lautenberger JA, Chinn L, McIntosh C, Johnson RC, Sezgin E, Kessing B, Malasky M, Hendrickson SL, Li G, Pontius J, Tang M, An P, Winkler CA, Limou S, Le Clerc S, Delaneau O, Zagury JF, Schuitemaker H, van Manen D, Bream JH, Gomperts ED, Buchbinder S, Goedert JJ, Kirk GD, O'Brien SJ, Genome-wide association study implicates PARD3B-based AIDS restriction. J INFECT DIS 2011;203 (10):1491-1502 [PubMed]

van der Helm JJ, Prins M, del Amo J, Bucher HC, Chêne G, Dorrucci M, Gill J, Hamouda O, Sannes M, Porter K, Geskus RB [Contributors: Meyer L, Pillay D, Rosinska M, Sabin C, Touloumi G, Lodi S, Coughlin K, Walker S, Babiker A, de Luca A, Fisher M, Muga R, Zangerle R, Kelleher T, Ramacciotti T, Gelgor L, Cooper D, Smith D, Bruun Jørgensen L, Nielsen C, Pedersen C, Lutsar I, Dabis F, Thiebaut R, Masquelier B, Costagliola D, Guiguet M, Vanhems P, Chaix ML, Ghosn J, Boufassa F, Kücherer C, Bartmeyer B, Pantazis N, Hatzakis A, Paraskevis D, Karafoulidou A, Rezza G, Balotta C, D'Arminio Monforte A, Cozzi-Lepri A, Schuitemaker H, Brubakk O, Kran AMB, Rosinska M, Tor J, de Olalla PG, Cayla J, del Romero J, Pérez-Hoyos S, Rickenbach M, Francioli P, Malyuta R, Brettle R, Murphy G, Johnson A, Phillips A, Delpech V, Jaffe H, Morrison C, Salata R, Mugerwa R, Chipato T, Amornkul P]] , The hepatitis C epidemic among HIV-positive MSM: incidence estimates from 1990 to 2007. AIDS 2011;25 (8):1083-1091 [PubMed]

van Gils MJ. Cross-rreactive neutralizing humoral immunity in HIV-1 disease: dynamics of host-pathogen interactions. s.l.: s.n.; 2011. 263p. ISBN 9789490371692 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Schuitemaker H; copromotor(s): )

van Gils MJ, Bunnik EM, Boeser-Nunnink BD, Burger JA, Terlouw-Klein M, Verwer N, Schuitemaker H, Longer V1V2 region with increased number of potential N-linked glycosylation sites in the HIV-1 envelope glycoprotein protects against HIV-specific neutralizing antibodies. J VIROL 2011;85 (14):6986-6995 [PubMed]

van Gils MJ, Edo-Matas D, Bowles EJ, Burger JA, Stewart-Jones GB, Schuitemaker H, Evolution of human immunodeficiency virus type 1 in a patient with cross-reactive neutralizing activity in serum. J VIROL 2011;85 (16):8443-8448 [PubMed]

van Manen D. The influence of host genetic factors on HIV-1 infection. s.l.: s.n.; 2011. 186p. ISBN 9789490371937 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Schuitemaker H; copromotor(s): van 't Wout AB)

van Manen D, Delaneau O, Kootstra NA, Boeser-Nunnink BD, Limou S, Bol SM, Burger JA, Zwinderman AH, Moerland PD, van 't Slot R, Zagury JF, van 't Wout AB, Schuitemaker H, Genome-wide association scan in HIV-1-infected individuals identifying variants influencing disease course. PLOS ONE 2011;6 (7):e22208 [PubMed]

van Manen D, Gras L, Boeser-Nunnink BD, van Sighem AI, Maurer I, Mangas Ruiz MM, Harskamp AM, Steingrover R, Prins JM, de Wolf F, van 't Wout AB, Schuitemaker H, Rising HIV-1 viral load set point at a population level coincides with a fading impact of host genetic factors on HIV-1 control. AIDS 2011;25 (18):2217-2226 [PubMed]

[Contributors: Jonsson M, Fusco JS, Cole SR, Thomas JC, Porter K, Kaufman JS, Davidian M, White AD, Hartmann KE, Eron JJ Jr, del Amo J, Meyer L, Bucher HC, Chene G, Pillay D, Prins M, Rosinska M, Sabin C, Touloumi G, Lodi S, Coughlin K, Walker S, Babiker A, de Luca A, Fisher M, Muga R, Kaldor J, Kelleher T, Ramacciotti T, Gelgor L, Cooper D, Smith D, Gill J, Jørgensen LB, Nielsen C, Pedersen C, Lutsar I, Dabis F, Thiebaut R, Masquelier B, Costagliola D, Guiguet M, Vanhems P, Chaix ML, Ghosn J, Boufassa F, Hamouda O, Kücherer C, Bartmeyer B, Pantazis N, Hatzakis A, Paraskevis D, Karafoulidou A, Rezza G, Dorrucci M, Balotta C, D'Arminio Monforte A, Cozzi-Lepri A, Geskus R, van der Helm J, Schuitemaker H, Sannes M, Brubakk O, Bakken Kran AM, Rosinska M, Gniewosz J, Camacho R, Smolskaya T, Tor J, Garcia de Olalla P, Cayla J, del Romero J, Pérez-Hoyos S, Rickenbach M, Francioli P, Malyuta R, Brettle R, Delpech V, Lattimore S, Murphy G, Johnson A, Phillips A, Jaffe H, Morrison C, Salata R, Mugerwa R, Chipato T, Amornkul P]] , Timing of HAART initiation and clinical outcomes in human immunodeficiency virus type 1 seroconverters. ARCH INTERN MED 2011;171 (17):1560-1569 [PubMed]

Bunnik EM. HIV-1 neutralizing humoral immunity, viral evolutionand disease progression. s.l.: s.n.; 2010. 240p. ISBN 9789085599258 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Schuitemaker H; copromotor(s): )

Bunnik EM, Euler Z, Welkers MRA, Boeser-Nunnink BDM, Grijsen ML, Prins JM, Schuitemaker H, Adaptation of HIV-1 envelope gp120 to humoral immunity at a population level. NAT MED 2010;16 (9):995-997 [PubMed]

Bunnik EM, Lobbrecht MSD, van Nuenen AC, Schuitemaker H, Escape from autologous humoral immunity of HIV-1 is not associated with a decrease in replicative capacity. VIROLOGY 2010;397 (1):224-230 [PubMed]

Bunnik EM, van Gils MJ, Lobbrecht MSD, Pisas L, Nanlohy NM, van Baarle D, van Nuenen AC, Hessell AJ, Schuitemaker H, Emergence of monoclonal antibody b12-resistant human immunodeficiency virus type 1 variants during natural infection in the absence of humoral or cellular immune pressure. J GEN VIROL 2010;91 (Part 5):1354-1364 [PubMed]

Edo-Matas D, van Gils MJ, Bowles EJ, Navis M, Rachinger A, Boeser-Nunnink B, Stewart-Jones GB, Kootstra NA, Wout ABvt, Schuitemaker H, Genetic composition of replication competent clonal HIV-1 variants isolated from peripheral blood mononuclear cells (PBMC), HIV-1 proviral DNA from PBMC and HIV-1 RNA in serum in the course of HIV-1 infection. VIROLOGY 2010;405 (2):492-504 [PubMed]

Euler Z, van Gils MJ, Bunnik EM, Phung P, Schweighardt B, Wrin T, Schuitemaker H, Cross-Reactive Neutralizing Humoral Immunity Does Not Protect from HIV Type 1 Disease Progression. J INFECT DIS 2010;201 (7):1045-1053 [PubMed]

Ferreira MAR, Mangino M, Brumme CJ, Zhao ZZ, Medland SE, Wright MJ, Nyholt DR, Gordon S, Campbell M, McEvoy BP, Henders A, Evans DM, Lanchbury JS, Pereyra F, Walker BD, Haas DW, Soranzo N, Spector TD, de Bakker PIW, Frazer IH, Montgomery GW, Martin NG [Contributors: Agan B, Agarwal S, Allen B, Altidor S, Altschuler E, Ambardar S, Anastos K, Anderson B, Andrady U, Angell T, Appelbaum J, Arnold K, Arroyo J, Arthur E, Barbaro D, Barrett T, Barrie W, Barthel V, Bartlett ME, Barton S, Basden P, Basgoz N, Bellos N, Berger J, Bernard A, Bernard N, Blair D, Bodner S, Bolan R, Boudreaux E, Braun J, Brndjar J, Brooks E, Brown K, Brown S, Bryant S, Bryson R, Buchbinder S, Bullock D, Burack J, Busalacchi M, Bush L, Cafaro V, Campbell J, Cardosi B, Carlson R, Carmichael K, Carr P, Carrington M, Cavacuiti C, Celestin G, Chaborek M, Chau J, Chez N, Cimoch P, Cohen DE, Cohn B, Cohn L, Conway B, Cooper D, Cooper J, Cornellson B, Cowles A, Cox D, Cox-Iyamu R, Cuchural G, Daily M, Daly J, Dang S, Davis B, Davis K, de Koning P, DeCardi Hladek M, Dechter M, Deeks S, DeFoto J, DeJesus E, Dennis DT, Dolan M, Duggan J, Dunn M, Egenes K, Ellerin T, Elliott K, Eron J, Fangman J, Ferlazzo H, Figueroa Y, Fiola T, Fisk S, Flaherty M, Fleenor-Ford A, Forster A, Fralich T, Francke E, Frankel R, Freedburg K, French N, Fuchs JD, Fuller J, Gaberman JI, Gallant J, Gandhi R, Ganesan A, Garcia E, Gardner A, Garver P, Gastaldo J, Gathe J, Gaultier C, Gebre W, Gelman M, Gilman F, Gilmore J, Gimbarevsky B, Glaser J, Goepfert P, Good G, Gottlieb M, Goulston C, Grimm W, Groger R, Guiteau J, Gurley TD, Haber S, Hale B, Halpenny R, Hardin T, Hardy WD, Hargan T, Harrigan R, Haston J, Hawkins T, Hellinger W, Henderson R, Henderson T, Henry K, Hermann S, Hernandez S, Hicks C, Hoffman R, Holland C, Horton J, Hoskinson S, Hsu RK, Huber J, Huhn G, Humphrey R, Hupert M, Hurtado R, Illeman M, Israelski D, Jellinger R, Jessen H, John M, Johnson K, Jones M, Jordan W, Kauffman C, Keba A, Khanlou H, Killian R, Kim A, Kim D, Kinder F, Kirchner J, Kish MA, Kocurek K, Kogelman L, Kojic EM, Kortuis T, Kovacs J, Kreiswirth S, Kuldanek G, Kurisu W, Lackey P, Ladan A, Lanzafame M, Lederman M, Lee D, Lee E, Lee J, Lee M, LeGrand J, Lemoine J, Levin S, Levy J, Liguori M, Lin N, Little S, Livine R, Llibre JM, Lopez A, Loutfy M, Loy D, Lubarda B, Magee T, Maksvytis H, Man A, Mancuso S, Marconi V, Markowitz M, Marques R Jr, Martin W, Mayer G, Mayer K, McCrone C, McDonald C, McGhee T, McIntyre D, McLean PS, McNett M, Mead H, Mechling K, Melia M, Metroka C, Meyer-Olson D, Michael B, Miller A, Montana J, Montgomery K, Morice A, Mounzer K, Munoz M, Nagin I, Nahass R, Ndung'u T, Nelson S, Nielsen C, Norene D, Novales S, O'Connor D, O'Donnell L, Oldfield E, Olender S, Ojikutu B, Owens W, Panzer T, Parks B, Pattison J, Pavlatos A, Perlmutter A, Pierce MN, Pollak D, Rowe E, Pressnell R, Price L, Proia L, Prokesch R, Prutch P, Pujet H, Rausch M, Ravinshankar J, Restrepo D, Rhame F, Richards C, Richman DD, Robbins G, Rose R 3rd, Rosenthal D, Ross P, Rubin D, Rumbaugh E, Sanchez W, Sanjana V, Santiago S, Santos R, Sax P, Scherman D, Schmidt W, Shrader S, Schuitemaker H, Scribner A, Sestak P, Shalit P, Shay W, Sherman J, Shirvani V, Sims J, Sizemore J, Slotten R, Smiddy J, Sokol-Anderson M, Somogi R, Sordjan R, Sosman J, Stabile P, Stapleton J, Starrett S, Staszkow K, Stearn B, Stellbrink HJ, Sterman L, Steyn T, Stone D, Stone V, Ta H, Tambussi G, Taplitz R, Tashmia K, Tavari D, Tedaldi E, Telenti A, Tierney M, Tillquist C, Tosiello L, Tremblay C, Triant VJ, Tribble M, Trinh P, Tuscher S, Vaccaro AJ, Valadas E, Vecino I, Wagner T, Walworth C, Wanidworanun C, Ward D, Warner D, Watson T, Weber K, Weber T, Webster D, Weinberg W, Weintrob A, Weis S, Wenger S, Werntz G, Wheeler D, White D, Wilkins E, Winston A, Wlodaver C, Wolf E, Wright D, Yang O, Yawetz S, Yurdin DL, Zabukovic B, Zachary K, Zeeman B, Baker B, Block B, Braaten C, Darrah AT, LaTour B, Lian J, McClurg C, Piechocka-Trocha A, Proudfoot J, Rothchild A, Toth I, Barefoot L, Bazner S, Cutrell E, Johnston M, Lemay P, Moss K, Oladehin O, Rosenberg R, Tinsley J, Tsao A, Pereyra F, Addo M, Allen T, Alter G, Altfeld M, Legall S, Walker B, Yu X, Burtt N, Carmago A, Crawford G, Crenshaw A, Davies L, Gabriel S, Gianniny L, Guiducci C, Brumme C, de Bakker P, Jia X, McLaren P, Haas D, Kuritzkes D, Gulick R, Ribaudo H, Deeks S, Henn M, Le Gall S, Heckerman D]] , Quantitative trait loci for CD4:CD8 lymphocyte ratio are associated with risk of type 1 diabetes and HIV-1 immune control. AM J HUM GENET 2010;86 (1):88-92 [PubMed]

Limou S, Coulonges C, Herbeck JT, van Manen D, An P, Le Clerc S, Delaneau O, Diop G, Taing L, Montes M, van't Wout AB, Gottlieb GS, Therwath A, Rouzioux C, Delfraissy JF, Lelièvre JD, Lévy Y, Hercberg S, Dina C, Phair J, Donfield S, Goedert JJ, Buchbinder S, Estaquier J, Schächter F, Gut I, Froguel P, Mullins JI, Schuitemaker H, Winkler C, Zagury JF, Multiple-Cohort Genetic Association Study Reveals CXCR6 as a New Chemokine Receptor Involved in Long-Term Nonprogression to AIDS. J INFECT DIS 2010;202 (6):908-915 [PubMed]

Pereyra F, Jia X, McLaren PJ, Telenti A, de Bakker PIW, Walker BD, Ripke S, Brumme CJ, Pulit SL, Carrington M, Kadie CM, Carlson JM, Heckerman D, Graham RR, Plenge RM, Deeks SG, Gianniny L, Crawford G, Sullivan J, Gonzalez E, Davies L, Camargo A, Moore JM, Beattie N, Gupta S, Crenshaw A, Burtt NP, Guiducci C, Gupta N, Gao X, Qi Y, Yuki Y, Piechocka-Trocha A, Cutrell E, Rosenberg R, Moss KL, Lemay P, O'Leary J, Schaefer T, Verma P, Toth I, Block B, Baker B, Rothchild A, Lian J, Proudfoot J, Alvino DML, Vine S, Addo MM, Allen TM, Altfeld M, Henn MR, Le Gall S, Streeck H, Haas DW, Kuritzkes DR, Robbins GK, Shafer RW, Gulick RM, Shikuma CM, Haubrich R, Riddler S, Sax PE, Daar ES, Ribaudo HJ, Agan B, Agarwal S, Ahern RL, Allen BL, Altidor S, Altschuler EL, Ambardar S, Anastos K, Anderson B, Anderson V, Andrady U, Antoniskis D, Bangsberg D, Barbaro D, Barrie W, Bartczak J, Barton S, Basden P, Basgoz N, Bazner S, Bellos NC, Benson AM, Berger J, Bernard NF, Bernard AM, Birch C, Bodner SJ, Bolan RK, Boudreaux ET, Bradley M, Braun JF, Brndjar JE, Brown SJ, Brown K, Brown ST, Burack J, Bush LM, Cafaro V, Campbell O, Campbell J, Carlson RH, Carmichael JK, Casey KK, Cavacuiti C, Celestin G, Chambers ST, Chez N, Chirch LM, Cimoch PJ, Cohen D, Cohn LE, Conway B, Cooper DA, Cornelson B, Cox DT, Cristofano MV, Cuchural G Jr, Czartoski JL, Dahman JM, Daly JS, Davis BT, Davis K, Davod SM, DeJesus E, Dietz CA, Dunham E, Dunn ME, Ellerin TB, Eron JJ, Fangman JJW, Farel CE, Ferlazzo H, Fidler S, Fleenor-Ford A, Frankel R, Freedberg KA, French NK, Fuchs JD, Fuller JD, Gaberman J, Gallant JE, Gandhi RT, Garcia E, Garmon D, Gathe JC Jr, Gaultier CR, Gebre W, Gilman FD, Gilson I, Goepfert PA, Gottlieb MS, Goulston C, Groger RK, Gurley TD, Haber S, Hardwicke R, Hardy WD, Harrigan PR, Hawkins TN, Heath S, Hecht FM, Henry WK, Hladek M, Hoffman RP, Horton JM, Hsu RK, Huhn GD, Hunt P, Hupert MJ, Illeman ML, Jaeger H, Jellinger RM, John M, Johnson JA, Johnson KL, Johnson H, Johnson K, Joly J, Jordan WC, Kauffman CA, Khanlou H, Killian RK, Kim AY, Kim DD, Kinder CA, Kirchner JT, Kogelman L, Kojic EM, Korthuis PT, Kurisu W, Kwon DS, LaMar M, Lampiris H, Lanzafame M, Lederman MM, Lee DM, Lee JML, Lee MJ, Lee ETY, Lemoine J, Levy JA, Llibre JM, Liguori MA, Little SJ, Liu AY, Lopez AJ, Loutfy MR, Loy D, Mohammed DY, Man A, Mansour MK, Marconi VC, Markowitz M, Marques R, Martin JN, Martin HL Jr, Mayer KH, McElrath MJ, McGhee TA, McGovern BH, McGowan K, McIntyre D, Mcleod GX, Menezes P, Mesa G, Metroka CE, Meyer-Olson D, Miller AO, Montgomery K, Mounzer KC, Nagami EH, Nagin I, Nahass RG, Nelson MO, Nielsen C, Norene DL, O'Connor DH, Ojikutu BO, Okulicz J, Oladehin OO, Oldfield EC 3rd, Olender SA, Ostrowski M, Owen WF Jr, Pae E, Parsonnet J, Pavlatos AM, Perlmutter AM, Pierce MN, Pincus JM, Pisani L, Price LJ, Proia L, Prokesch RC, Pujet HC, Ramgopal M, Rathod A, Rausch M, Ravishankar J, Rhame FS, Richards CS, Richman DD, Rodes B, Rodriguez M, Rose RC 3rd, Rosenberg ES, Rosenthal D, Ross PE, Rubin DS, Rumbaugh E, Saenz L, Salvaggio MR, Sanchez WC, Sanjana VM, Santiago S, Schmidt W, Schuitemaker H, Sestak PM, Shalit P, Shay W, Shirvani VN, Silebi VI, Sizemore JM Jr, Skolnik PR, Sokol-Anderson M, Sosman JM, Stabile P, Stapleton JT, Starrett S, Stein F, Stellbrink HJ, Sterman FL, Stone VE, Stone DR, Tambussi G, Taplitz RA, Tedaldi EM, Theisen W, Torres R, Tosiello L, Tremblay C, Tribble MA, Trinh PD, Tsao A, Ueda P, Vaccaro A, Valadas E, Vanig TJ, Vecino I, Vega VM, Veikley W, Wade BH, Walworth C, Wanidworanun C, Ward DJ, Warner DA, Weber RD, Webster D, Weis S, Wheeler DA, White DJ, Wilkins E, Winston A, Wlodaver CG, van't Wout A, Wright DP, Yang OO, Yurdin DL, Zabukovic BW, Zachary KC, Zeeman B, Zhao M, The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. SCIENCE 2010;330 (6010):1551-1557 [PubMed]

Rachinger A. HIV-1 superinfection in homosexual men. s.l.: s.n.; 2010. 95p. ISBN 9789088911569 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Schuitemaker H; copromotor(s): van 't Wout AB)

Rachinger A, Stolte IG, van de Ven TD, Burger JA, Prins M, Schuitemaker H, van 't Wout AB, Absence of HIV-1 Superinfection 1 Year after Infection between 1985 and 1997 Coincides with a Reduction in Sexual Risk Behavior in the Seroincident Amsterdam Cohort of Homosexual Men. CLIN INFECT DIS 2010;50 (9):1309-1315 [PubMed]

Rachinger A, Ven TDvd, Burger JA, Schuitemaker H, Wout ABvt, Evaluation of pre-screening methods for the identification of HIV-1 superinfection. J VIROL METHODS 2010;165 (2):311-317 [PubMed]

van Gils MJ, Bunnik EM, Burger JA, Jacob Y, Schweighardt B, Wrin T, Schuitemaker H, Rapid Escape from Preserved Cross-Reactive Neutralizing Humoral Immunity without Loss of Viral Fitness in HIV-1-Infected Progressors and Long-Term Nonprogressors. J VIROL 2010;84 (7):3576-3585 [PubMed]

van Gils MJ, Edo-Matas D, Schweighardt B, Wrin T, Schuitemaker H, High prevalence of neutralizing activity against multiple unrelated human immunodeficiency virus type 1 (HIV-1) subtype B variants in sera from HIV-1 subtype B-infected individuals: evidence for subtype-specific rather than strain-specific neutralizing activity. J GEN VIROL 2010;91 (Part 1):250-258 [PubMed]

van Gils MJ, Schuitemaker H, Correlations between HIV-1 clades and HIV-1 antibody neutralization sensitivity: significant for vaccine development?. CURR HIV RES 2010;8 (8):579-586 [PubMed]

van Manen D, Kootstra NA, Boeser-Nunnink B, Handulle MAM, van 't Wout AB, Schuitemaker H, Association of HLA-C and HCP5 gene regions with the clinical course of HIV-1 infection (vol 23, pg 19, 2009). AIDS 2010;24 (6):939

Wolbers M, Babiker A, Sabin C, Young J, Dorrucci M, Chêne G, Mussini C, Porter K, Bucher HC [Contributors: del Amo J, Meyer L, Bucher HC, Chêne G, Pillay D, Prins M, Rosinska M, Sabin C, Touloumi G, Porter K, Lodi S, Coughlin K, Walker S, Babiker A, Darbyshire J, de Luca A, Fisher M, Muga R, Kaldor J, Kelleher T, Ramacciotti T, Gelgor L, Cooper D, Smith D, Gill J, Jørgensen LB, Nielsen C, Lutsar I, Dabis F, Thiebaut R, Masquelier B, Costagliola D, Guiguet M, Vanhems P, Chaix ML, Ghosn J, Boufassa F, Hamouda O, Kucherer C, Pantazis N, Hatzakis A, Paraskevis D, Karafoulidoua A, Rezza G, Dorrucci M, Balotta C, Monforte AdA, Cozzi-Lepri A, van der Helm J, Geskus R, Schuitemaker H, Sannes M, Brubakk O, Eskild A, Bruun JN, Rosinska M, Gniewosz J, Camacho R, Smolskaya T, Tor J, de Olalla PG, Cayla J, del Romero J, Pérez-Hoyos S, Rickenbach M, Francioli P, Malyuta R, Brettle R, Delpech V, Lattimore S, Murphy G, Parry J, Gill N, Lee C, Johnson A, Phillips A, Jaffe H]] , Pretreatment CD4 cell slope and progression to AIDS or death in HIV-infected patients initiating antiretroviral therapy--the CASCADE collaboration: a collaboration of 23 cohort studies. PLOS MED 2010;7 (2):e1000239 [PubMed]

Bol SM, van Remmerden Y, Sietzema JG, Kootstra NA, Schuitemaker H, van 't Wout AB, Donor variation in in vitro HIV-1 susceptibility of monocyte-derived macrophages. VIROLOGY 2009;390 (2):205-211 [PubMed]

Bunnik EM, van Gils MJ, Lobbrecht MSD, Pisas L, van Nuenen AC, Schuitemaker H, Changing sensitivity to broadly neutralizing antibodies b12, 2G12, 2F5, and 4E10 of primary subtype B human immunodeficiency virus type 1 variants in the natural course of infection. VIROLOGY 2009;390 (2):348-355 [PubMed]

Coakley E, Reeves JD, Huang W, Mangas-Ruiz M, Maurer I, Harskamp AM, Gupta S, Lie Y, Petropoulos CJ, Schuitemaker H, van 't Wout AB, Comparison of human immunodeficiency virus type 1 tropism profiles in clinical samples by the Trofile and MT-2 assays. ANTIMICROB AGENTS CH 2009;53 (11):4686-4693 [PubMed]

Fenyö EM, Heath A, Dispinseri S, Holmes H, Lusso P, Zolla-Pazner S, Donners H, Heyndrickx L, Alcami J, Bongertz V, Jassoy C, Malnati M, Montefiori D, Moog C, Morris L, Osmanov S, Polonis V, Sattentau Q, Schuitemaker H, Sutthent R, Wrin T, Scarlatti G, International Network for Comparison of HIV Neutralization Assays: The NeutNet Report. PLOS ONE 2009;4 (2):e4505 [PubMed]

Navis M. Cellular immunity driving HIV-1 evolution. S.l.: s.n.; 2009. 222p. ISBN 9789090238906 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Schuitemaker H; copromotor(s): Kootstra NA)

Polonis VR, Schuitemaker H, Bunnik EM, Brown BK, Scarlatti G, Impact of host cell variation on the neutralization of HIV-1 in vitro. CURR OPIN HIV AIDS 2009;4 (5):400-407 [PubMed]

Rits MAN. Cellular factors involved in HIV-1 replication. s.l.: s.n.; 2009. 169p. [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Schuitemaker H; copromotor(s): Kootstra NA)

van Gils MJ, Euler Z, Schweighardt B, Wrin T, Schuitemaker H, Prevalence of cross-reactive HIV-1-neutralizing activity in HIV-1-infected patients with rapid or slow disease progression. AIDS 2009;23 (18):2405-2414 [PubMed]

van Loo KMJ, Van Schijndel JE, Van Zweeden M, van Manen D, Trip MD, Petersen DC, Schuitemaker H, Hayes VM, Martens GJM, Correlation Between HIV-1 Seropositivity and Prevalence of a gamma-Secretase Polymorphism in Two Distinct Ethnic Populations. J MED VIROL 2009;81 (11):1847-1851 [PubMed]

van Manen D, Kootstra NA, Boeser-Nunnink B, Handulle MA, Vanʼt Wout AB, Schuitemaker H, Association of HLA-C and HCP5 gene regions with the clinical course of HIV-1 infection. AIDS 2009;23 (1):19-28 [PubMed]

Blaak H, Boers PHM, van der Ende ME, Schuitemaker H, Osterhaus ADME, CCR5-restricted HIV type 2 variants from long-term aviremic individuals are less sensitive to inhibition by beta-chemokines than low pathogenic HIV type 1 variants. AIDS RES HUM RETROV 2008;24 (3):473-484 [PubMed]

Bunnik EM, Pisas L, van Nuenen AC, Schuitemaker H, Autologous neutralizing humoral immunity and evolution of the viral envelope in the course of subtype B human immunodeficiency virus type 1 infection. J VIROL 2008;82 (16):7932-7941 [PubMed]

Navis M, Edo Matas D, Rachinger A, Koning FA, van Swieten P, Kootstra NA, Schuitemaker H, Molecular Evolution of Human Immunodeficiency Virus Type 1 upon Transmission between Human Leukocyte Antigen Disparate Donor-Recipient Pairs. PLOS ONE 2008;3 (6):e2422 [PubMed]

Navis M, Miedema F, Schuitemaker H, Cytotoxic T lymphocyte responses in HIV-1 infected long term non progressors: lessons for vaccine design. FUTURE HIV THER 2008;2 (4):351-361

Navis M, Schellens IMM, van Swieten P, Borghans JAM, Miedema F, Kootstra NA, van Baarle D, Schuitemaker H, A nonprogressive clinical course in HIV-infected individuals expressing human leukocyte antigen B57/5801 is associated with preserved CD8+ T lymphocyte responsiveness to the HW9 epitope in Nef. J INFECT DIS 2008;197 (6):871-879 [PubMed]

Rachinger A, Navis M, van Assen S, Groeneveld PHP, Schuitemaker H, Recovery of viremic control after superinfection with pathogenic HIV type 1 in a long-term elite controller of HIV type 1 infection. CLIN INFECT DIS 2008;47 (11):e86-e89 [PubMed]

Steingrover R, Pogány K, Fernandez Garcia E, Jurriaans S, Brinkman K, Schuitemaker H, Miedema F, Lange JM, Prins JM, HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy. AIDS 2008;22 (13):1583-1588 [PubMed]

Terpstra FG, van 't Wout AB, Schuitemaker H, van Engelenburg FAC, Dekkers DWC, Verhaar R, de Korte D, Verhoeven AJ, Potential and limitation of UVC irradiation for the inactivation of pathogens in platelet concentrates. TRANSFUSION 2008;48 (2):304-313 [PubMed]

van Manen D, Rits MAN, Beugeling C, van Dort K, Schuitemaker H, Kootstra NA, The effect of Trim5 polymorphisms on the clinical course of HIV-1 infection. PLOS PATHOG 2008;4 (2):e18 [PubMed]

van 't Wout AB, Schuitemaker H, Kootstra NA, Isolation and propagation of HIV-1 on peripheral blood mononuclear cells. NAT PROTOC 2008;3 (3):363-370 [PubMed]

Bunnik EM, Quakkelaar ED, van Nuenen AC, Boeser-Nunnink B, Schuitemaker H, Increased neutralization sensitivity of recently emerged CXCR4-using human immunodeficiency virus type 1 strains compared to coexisting CCR5-using variants from the same patient. J VIROL 2007;81 (2):525-531 [PubMed]

Choudhary SK, Vrisekoop N, Jansen CA, Otto SA, Schuitemaker H, Miedema F, Camerini D, Low immune activation despite high levels of pathogenic human immunodeficiency virus type 1 results in long-term asymptomatic disease. J VIROL 2007;81 (16):8838-8842 [PubMed]

Kootstra NA, Navis M, Beugeling C, van Dort KA, Schuitemaker H, The presence of the Trim5alpha escape mutation H87Q in the capsid of late stage HIV-1 variants is preceded by a prolonged asymptomatic infection phase. AIDS 2007;21 (15):2015-2023 [PubMed]

Navis M, Schellens I, van Baarle D, Borghans J, van Swieten P, Miedema F, Kootstra N, Schuitemaker H, Viral replication capacity as a correlate of HLA B57/B5801-associated nonprogressive HIV-1 infection. J IMMUNOL 2007;179 (5):3133-3143 [PubMed]

Quakkelaar ED. Antibody neutralization of HIV-1. s.l.: s.n.; 2007. 158p. ISBN 9789090216492 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Schuitemaker H; copromotor(s): )

Quakkelaar ED, Beaumont T, van Nuenen AC, van Alphen FPJ, Boeser-Nunnink BDM, van 't Wout AB, Schuitemaker H, T cell line passage can select for pre-existing neutralization-sensitive variants from the quasispecies of primary human immunodeficiency virus type-1 isolates. VIROLOGY 2007;359 (1):92-104 [PubMed]

Quakkelaar ED, Bunnik EM, van Alphen FPJ, Boeser-Nunnink BDM, van Nuenen AC, Schuitemaker H, Escape of human immunodeficiency virus type 1 from broadly neutralizing antibodies is not associated with a reduction of viral replicative capacity in vitro. VIROLOGY 2007;363 (2):447-453 [PubMed]

Quakkelaar ED, van Alphen FPJ, Boeser-Nunnink BDM, van Nuenen AC, Pantophlet R, Schuitemaker H, Susceptibility of recently transmitted subtype B human immunodeficiency virus type 1 variants to broadly neutralizing antibodies. J VIROL 2007;81 (16):8533-8542 [PubMed]

Sankatsing SUC, Cornelissen M, Kloosterboer N, Crommentuyn KML, Bosch TM, Mul FP, Jurriaans S, Huitema ADR, Beijnen JH, Lange JMA, Prins JM, Schuitemaker H, Antiviral activity of HIV type 1 protease inhibitors nelfinavir and indinavir in vivo is not influenced by P-glycoprotein activity on CD4+ T cells. AIDS RES HUM RETROV 2007;23 (1):19-27 [PubMed]

Terpstra FG. Viral safety of blood and plasma products. s.l.: s.n.; 2007. 188p. ISBN 9789090219295 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Schuitemaker H; copromotor(s): van 't Wout AB, Over J)

Terpstra FG, Kleijn M, Koenderman AHL, Over J, van Engelenburg FAC, Schuitemaker H, van 't Wout AB, Viral safety of C1-inhibitor NF. BIOLOGICALS 2007;35 (3):173-181 [PubMed]

Terpstra FG, van den Blink AE, Bos LM, Boots AGC, Brinkhuis FHM, Gijsen E, van Remmerden Y, Schuitemaker H, van 't Wout AB, Resistance of surface-dried virus to common disinfection procedures. J HOSP INFECT 2007;66 (4):332-338 [PubMed]

Tsegaye A, Ran L, Wolday D, Petros B, Dorigo W, Piriou E, Messele T, Sanders E, Tilahun T, Eshetu D, Schuitemaker H, Coutinho RA, Miedema F, Borghans J, van Baarle D, HIV-1 subtype C gag-specific T-cell responses in relation to human leukocyte antigens in a diverse population of HIV-infected Ethiopians. JAIDS-J ACQ IMM DEF 2007;45 (4):389-400 [PubMed]

Vermeulen JN, Prins JM, Bunnik E, Hack CE, Jurriaans S, Miedema F, Lange JMA, Schuitemaker H, Intravenous immunoglobulin (IVIG) treatment for modulation of immune activation in human immunodeficiency virus type 1 infected therapy-naive individuals. AIDS RES HUM RETROV 2007;23 (11):1348-1353 [PubMed]

Blaak H, van der Ende ME, Boers PHM, Schuitemaker H, Osterhaus ADME, In vitro replication capacity of HIV-2 variants from long-term aviremic individuals. VIROLOGY 2006;353 (1):144-154 [PubMed]

Geels MJ, Jansen CA, Baan E, de Cuyper IM, van Schijndel GJM, Schuitemaker H, Goudsmit J, Pollakis G, Miedema F, Paxton WA, van Baarle D, CTL escape and increased viremia irrespective of HIV-specific CD4+ T-helper responses in two HIV-infected individuals. VIROLOGY 2006;345 (1):209-219 [PubMed]

Koppelman MHGM. Viral safety of blood donations. Molecular detection of blood transmittable viruses. S.l.: s.n.; 2006. 159p. ISBN 9789064641343 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Schuitemaker H; copromotor(s): Reesink HW, Zaaijer HL)

Krol A, Lensen R, Veenstra J, Prins M, Schuitemaker H, Coutinho RA, Impact of CCR5 Delta32/+ deletion on herpes zoster among HIV-1-infected homosexual men. EUR J EPIDEMIOL 2006;21 (6):469-473 [PubMed]

Blaak H, Boers PHM, Gruters RA, Schuitemaker H, van der Ende ME, Osterhaus ADME, CCR5, GPR15, and CXCR6 are major coreceptors of human immunodeficiency virus type 2 variants isolated from individuals with and without plasma viremia. J VIROL 2005;79 (3):1686-1700 [PubMed]

Choudhary SK, Choudhary NR, Kimbrell KC, Colasanti J, Ziogas A, Kwa D, Schuitemaker H, Camerini D, R5 human immunodeficiency virus type 1 infection of fetal thymic organ culture induces cytokine and CCR5 expression. J VIROL 2005;79 (1):458-471 [PubMed]

Geskus RB, Meyer L, Hubert JB, Schuitemaker H, Berkhout B, Rouzioux C, Theodorou ID, Delfraissy JF, Prins M, Coutinho RA, Causal pathways of the effects of age and the CCR5-Delta32, CCR2-64I, and SDF-1 3'A alleles on AIDS development. JAIDS-J ACQ IMM DEF 2005;39 (3):321-326 [PubMed]

Kloosterboer N, Groeneveld PHP, Jansen CA, van der Vorst TJK, Koning F, Winkel CN, Duits AJ, Miedema F, van Baarle D, van Rij RP, Brinkman K, Schuitemaker H, Natural controlled HIV infection: Preserved HIV-specific immunity despite undetectable replication competent virus. VIROLOGY 2005;339 (1):70-80 [PubMed]

Koning FA, Koevoets C, van der Vorst TJK, Schuitemaker H, Sensitivity of primary R5 HTV-1 to inhibition by RANTES correlates with sensitivity to small-molecule R5 inhibitors. ANTIVIR THER 2005;10 (2):231-237 [PubMed]

Koning FA, Otto SA, Hazenberg MD, Dekker L, Prins M, Miedema F, Schuitemaker H, Low-level CD4(+) T cell activation is associated with low susceptibility to HIV-1 infection. J IMMUNOL 2005;175 (9):6117-6122 [PubMed]

Koning FA, van der Vorst TJK, Schuitemaker H, Low levels of human immunodeficiency virus type 1 DNA in high-risk seronegative men. J VIROL 2005;79 (10):6551-6553 [PubMed]

Kootstra NA, Schuitemaker H, Determination of cell tropism of HIV-1. METHODS MOL BIOL 2005;304:317-325 [PubMed]

Kootstra NA, Schuitemaker H. Determination of cell tropism of HIV-1 in: Zhu T, editors. Human retrovirus protocols: virology and molecular biology. Totowa, NJ: Humana Press Inc.; 2005., p. 317-325

Schuitemaker H, Kootstra NA, Determination of co-receptor usage of HIV-1. METHODS MOL BIOL 2005;304:327-332 [PubMed]

Schuitemaker H, Kootstra NA. Determination of co-receptor usage of HIV-1 in: Zhu T, editors. Human retrovirus protocols: virology and molecular biology. Totowa, NJ: Humana Press Inc.; 2005., p. 327-332

Schuitemaker H, Kootstra NA, Isolation, propagation, and titration of human immunodeficiency virus type 1 from peripheral blood of infected individuals. METHODS MOL BIOL 2005;304:17-24 [PubMed]

Schuitemaker H, Kootstra NA. Isolations, propagation, and titration of human immunodeficiency virus type 1 from peripheral blood of infected individuals in: Zhu T, editors. Human retrovirus protocols: virology and molecular biology. Totowa, NJ: Humana Press Inc.; 2005., p. 17-24

van der Bij AK, Kloosterboer N, Prins M, Boeser-Nunnink B, Geskus RB, Lange JMA, Coutinho RA, Schuitemaker H, GB virus C coinfection and HIV-1 disease progression: The Amsterdam Cohort Study. J INFECT DIS 2005;191 (5):678-685 [PubMed]

van der Bij AK, Kloosterboer N, Prins M, Boeser-Nunnink B, Geskus RB, Lange JMA, Coutinho RA, Schuitemaker H, GB virus C infection and survival in the Amsterdam Cohort study - Reply to George and to Stapleton et al. J INFECT DIS 2005;191 (12):2158-2160

Vrisekoop N, Sankatsing SUC, Jansen CA, Roos MTL, Otto SA, Schuitemaker H, Lange JMA, Prins JM, Miedema F, Short communication: No detrimental immunological effects of mycophenolate mofetil and HAART in treatment-naive acute and chronic HIV-1-infected patients. AIDS RES HUM RETROV 2005;21 (12):991-996 [PubMed]

Beaumont T, Quakkelaar E, van Nuenen A, Pantophlet R, Schuitemaker H, Increased sensitivity to CD4 binding site-directed neutralization following in vitro propagation on primary lymphocytes of a neutralization-resistant human immunodeficiency virus IIIB strain isolated from an accidentally infected laboratory worker. J VIROL 2004;78 (11):5651-5657 [PubMed]

Jurriaans S, Sankatsing SUC, Prins JM, Schuitemaker H, Lange J, van der Kuyl AC, Cornelissen M, HIV-1 seroreversion in an HIV-1-seropositive patient treated during acute infection with highly active antiretroviral therapy and mycophenolate mofetil. AIDS 2004;18 (11):1607-1608 [PubMed]

Koning FA. Determinants of host HIV-1 suspectibility and R5 HIV-1 evolution. S.l.: s.n.; 2004. 157p. ISBN 90-9018788-X [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Miedema F, Schuitemaker H; copromotor(s): )

Koning FA, Jansen CA, Dekker J, Kaslow RA, Dukers N, van Baarle D, Prins M, Schuitemaker H, Correlates of resistance to HIV-1 infection in homosexual men with high-risk sexual behaviour. AIDS 2004;18 (8):1117-1126 [PubMed]

Pollakis G, Abebe A, Kliphuis A, Chalaby MIM, Bakker M, Mengistu Y, Brouwer M, Goudsmit J, Schuitemaker H, Paxton WA, Phenotypic and genotypic comparisons of CCR5- and CXCR4-Tropic human immunodeficiency virus type 1 biological clones isolated from subtype C-infected individuals. J VIROL 2004;78 (6):2841-2852 [PubMed]

Sankatsing SUC, Jurriaans S, van Swieten P, van Leth F, Cornelissen M, Miedema F, Lange JMA, Schuitemaker H, Prins JM, Highly active antiretroviral therapy with or without mycophenolate mofetil in treatment-naive HIV-1 patients. AIDS 2004;18 (14):1925-1931 [PubMed]

Stalmeijer EHB, van Rij RP, Boeser-Nunnink B, Visser JA, Naarding MA, Schols D, Schuitemaker H, In vivo evolution of X4 human immunodeficiency virus type 1 variants in the natural course of infection coincides with decreasing sensitivity to CXCR4 antagonists. J VIROL 2004;78 (6):2722-2728 [PubMed]

Geels MJ, Cornelissen M, Schuitemaker H, Anderson K, Kwa D, Maas J, Dekker JT, Baan E, Zorgdrager F, van den Burg R, van Beelen M, Lukashov VV, Fu TM, Paxton WA, van der Hoek L, Dubey SA, Shiver JW, Goudsmit J, Identification of sequential viral escape mutants associated with altered T-cell responses in a human immunodeficiency virus type 1-infected individual. J VIROL 2003;77 (23):12430-12440 [PubMed]

Geskus RB, Miedema FA, Goudsmit J, Reiss P, Schuitemaker H, Coutinho RA, Prediction of residual time to AIDS and death based on markers and cofactors. JAIDS-J ACQ IMM DEF 2003;32 (5):514-521 [PubMed]

Hazenberg MD, Otto SA, Hamann D, Roos MTL, Schuitemaker H, de Boer RJ, Miedema F, Depletion of naive CD4 T cells by CXCR4-using HIV-1 variants occurs mainly through increased T-cell death and activation. AIDS 2003;17 (10):1419-1424 [PubMed]

Koning FA, Kwa D, Boeser-Nunnink B, Dekker J, Vingerhoed J, Hiemstra H, Schuitemaker H, Decreasing sensitivity to RANTES (regulated on activation, normally T cell-expressed and -secreted) neutralization of CC chemokine receptor 5-using, non-syncytium-inducing virus variants in the course of human immunodeficiency virus type 1 infection. J INFECT DIS 2003;188 (6):864-872 [PubMed]

Kwa D, Boeser-Nunnink B, Schuitemaker H, Lack of evidence for an association between a polymorphism in CX3CR1 and the clinical course of HIV infection or virus phenotype evolution. AIDS 2003;17 (5):759-761 [PubMed]

Kwa D, van Rij RP, Boeser-Nunnink B, Vingerhoed J, Schuitemaker H, Association between an interleukin-4 promoter polymorphism and the acquisition of CXCR4 using HIV-1 variants. AIDS 2003;17 (7):981-985 [PubMed]

Kwa D, Vingerhoed J, Boeser B, Schuitemaker H, Increased in vitro cytopathicity of CC chemokine receptor 5-restricted human immunodeficiency virus type 1 primary isolates correlates with a progressive clinical course of infection. J INFECT DIS 2003;187 (9):1397-1403 [PubMed]

Mulherin SA, O'Brien TR, Ioannidis JP, Goedert JJ, Buchbinder SP, Coutinho RA, Jamieson BD, Meyer L, Michael NL, Pantaleo G, Rizzardi GP, Schuitemaker H, Sheppard HW, Theodorou ID, Vlahov D, Rosenberg PS, Effects of CCR5-Delta32 and CCR2-64I alleles on HIV-1 disease progression: the protection varies with duration of infection. AIDS 2003;17 (3):377-387 [PubMed]

Sankatsing SUC, van Praag RME, van Rij RP, Rientsma R, Jurriaans S, Lange JMA, Prins JM, Schuitemaker H, Dynamics of the pool of infected resting CD4 HLA-DR- T lymphocytes in patients who started a triple class five-drug antiretroviral regimen during primary HIV-1 infection. ANTIVIR THER 2003;8 (2):137-142 [PubMed]

van Rij RP, Hazenberg MD, van Benthem BHB, Otto SA, Prins M, Miedema F, Schuitemaker H, Early viral load and CD4(+) T cell count, but not percentage of CCR5(+) or CXCR4(+) CD4(+) T cells, are associated with R5-to-X4 HIV type 1 virus evolution. AIDS RES HUM RETROV 2003;19 (5):389-398 [PubMed]

van Rij RP, Worobey M, Visser JA, Schuitemaker H, Evolution of R5 and X4 human immunodeficiency virus type 1 gag sequences in vivo: evidence for recombination. VIROLOGY 2003;314 (1):451-459 [PubMed]

Beaumont T. HIV-1 sensitivity to neutralization: biological and molecular studies. S.l.: s.n.; 2002. 115 blz.p. [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Miedema F; copromotor(s): Schuitemaker H)

Bolscher JGM, Nazmi K, Ran LJ, van Engelenburg FAC, Schuitemaker H, Veerman ECI, Nieuw Amerongen AV, Inhibition of HIV-1 IIIB and clinical isolates by human parotid, submandibular, sublingual and palatine saliva. EUR J ORAL SCI 2002;110 (2):149-156 [PubMed]

Davenport MP, Zaunders JJ, Hazenberg MD, Schuitemaker H, van Rij RP, Cell turnover and cell tropism in HIV-1 infection. TRENDS MICROBIOL 2002;10 (6):275-278 [PubMed]

Feinberg MB, McCune JM, Miedema F, Moore JP, Schuitemaker H, HIV tropism and CD4(+) T-cell depletion. NAT MED 2002;8 (6):537 [PubMed]

Goudsmit J, Bogaards JA, Jurriaans S, Schuitemaker H, Lange JMA, Coutinho RA, Weverling GJ, Naturally HIV-1 seroconverters with lowest viral load have best prognosis, but in time lose control of viraemia. AIDS 2002;16 (5):791-793 [PubMed]

Kwa IS. Host and viral factors in AIDS pathogenesis. S.l.: s.n.; 2002. 139p. [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Miedema F; copromotor(s): Schuitemaker H)

Labrijn AF, Koppelman MHGM, Verhagen J, Brouwer MC, Schuitemaker H, Hack CE, Huisman HG, Novel strategy for the selection of human recombinant Fab fragments to membrane proteins from a phage-display library. J IMMUNOL METHODS 2002;261 (1-2):37-48 [PubMed]

van Engelenburg FAC, Terpstra FG, Schuitemaker H, Moorer WR, The virucidal spectrum of a high concentration alcohol mixture. J HOSP INFECT 2002;51 (2):121-125 [PubMed]

van Rij RP. Chemokine receptors in HIV-1 infection and AIDS pathogenesis. S.l.: s.n.; 2002. 173p. [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Miedema F; copromotor(s): Schuitemaker H)

van Rij RP, Schuitemaker H, Host Genetic Factors in the Clinical Course of HIV-1 Infection: Chemokines and Chemokine Receptors. COMMUNITY GENET 2002;5 (2):88-101 [PubMed]

van Rij RP, van Praag RME, Prins JM, Rientsma R, Jurriaans S, Lange JMA, Schuitemaker H, Persistence of viral HLA-DR- CD4 T-cell reservoir during prolonged treatment of HIV-1 infection with a five-drug regimen. ANTIVIR THER 2002;7 (1):37-41 [PubMed]

van Rij RP, Visser JA, van Praag RME, Rientsma R, Prins JM, Lange JMA, Schuitemaker H, Both R5 and X4 human immunodeficiency virus type 1 variants persist during prolonged therapy with five antiretroviral drugs. J VIROL 2002;76 (6):3054-3058 [PubMed]

Wit FWNM, van Rij RP, Weverling GJ, Lange JMA, Schuitemaker H, CC chemokine receptor 5 delta32 and CC chemokine receptor 2 64I polymorphisms do not influence the virologic and immunologic response to antiretroviral combination therapy in human immunodeficiency virus type 1-infected patients. J INFECT DIS 2002;186 (12):1726-1732 [PubMed]

Beaumont T, van Nuenen A, Broersen S, Blattner WA, Lukashov VV, Schuitemaker H, Reversal of human immunodeficiency virus type 1 IIIB to a neutralization-resistant phenotype in an accidentally infected laboratory worker with a progressive clinical course. J VIROL 2001;75 (5):2246-2252 [PubMed]

Ioannidis JP, Rosenberg PS, Goedert JJ, Ashton LJ, Benfield TL, Buchbinder SP, Coutinho RA, Eugen-Olsen J, Gallart T, Katzenstein TL, Kostrikis LG, Kuipers H, Louie LG, Mallal SA, Margolick JB, Martinez OP, Meyer L, Michael NL, Operskalski E, Pantaleo G, Rizzardi GP, Schuitemaker H, Sheppard HW, Stewart GJ, Theodorou ID, Ullum H, Vicenzi E, Vlahov D, Wilkinson D, Workman C, Zagury JF, O'Brien TR, Effects of CCR5-Delta32, CCR2-64I, and SDF-1 3'A alleles on HIV-1 disease progression: An international meta-analysis of individual-patient data. ANN INTERN MED 2001;135 (9):782-795 [PubMed]

Koning FA, Schols D, Schuitemaker H, No selection for CCR5 coreceptor usage during parenteral transmission of macrophagetropic syncytium-inducing human immunodeficiency virus type 1. J VIROL 2001;75 (18):8848-8853 [PubMed]

Kreisberg JF, Kwa D, Schramm B, Trautner V, Connor R, Schuitemaker H, Mullins JI, van't Wout AB, Goldsmith MA, Cytopathicity of human immunodeficiency virus type 1 primary isolates depends on coreceptor usage and not patient disease status. J VIROL 2001;75 (18):8842-8847 [PubMed]

Kwa D, Vingerhoed J, Boeser-Nunnink B, Broersen S, Schuitemaker H, Cytopathic effects of non-syncytium-inducing and syncytium-inducing human immunodeficiency virus type 1 variants on different CD4(+)-T-cell subsets are determined only by coreceptor expression. J VIROL 2001;75 (21):10455-10459 [PubMed]

Messele T, Rinke de Wit TF, Brouwer M, Aklilu M, Birru T, Fontanet AL, Schuitemaker H, Hamann D, No difference in in vitro susceptibility to HIV type 1 between high-risk HIV-negative Ethiopian commercial sex workers and low-risk control subjects. AIDS RES HUM RETROV 2001;17 (5):433-441 [PubMed]

Reijers MH, Weverling GJ, Jurriaans S, Roos MT, Wit FW, Weigel HM, ten Kate RW, Mulder JW, Richter C, ter Hofstede HJ, Sprenger H, Hoetelmans RM, Schuitemaker H, Lange JM, The ADAM study continued: maintenance therapy after 50 weeks of induction therapy. AIDS 2001;15 (1):129-131 [PubMed]

van Praag RM, Prins JM, Roos MT, Schellekens PT, ten Berge IJ, Yong SL, Schuitemaker H, Eerenberg AJ, Jurriaans S, de Wolf F, Fox CH, Goudsmit J, Miedema F, Lange JM, OKT3 and IL-2 treatment for purging of the latent HIV-1 reservoir in vivo results in selective long-lasting CD4+ T cell depletion. J CLIN IMMUNOL 2001;21 (3):218-226 [PubMed]

Vyakarnam A, Eyeson J, teo I, Zuckerman M, Babaahmady K, Schuitemaker H, Shaunak S, Rostron T, Rowland-Jones S, Simmons G, Clapham P, Evidence for a post-entry barrier to R5 HIV-1 infection of CD4 memory T cells. AIDS 2001;15 (13):1613-1626 [PubMed]

Beaumont T, Broersen S, van Nuenen A, Huisman HG, de Roda Husman AM, Heeney JL, Schuitemaker H, Increased neutralization sensitivity and reduced replicative capacity of human immunodeficiency virus type 1 after short-term in vivo or in vitro passage through chimpanzees. J VIROL 2000;74 (17):7699-7707 [PubMed]

Blaak H, Ran LJ, Rientsma R, Schuitemaker H, Susceptibility of in vitro stimulated PBMC to infection with NSI HIV-1 is associated with levels of CCR5 expression and beta-chemokine production. VIROLOGY 2000;267 (2):237-246 [PubMed]

Blaak H, van't Wout AB, Brouwer M, Hooibrink B, Hovenkamp E, Schuitemaker H, In vivo HIV-1 infection of CD45RA(+)CD4(+) T cells is established primarily by syncytium-inducing variants and correlates with the rate of CD4(+) T cell decline. P NATL ACAD SCI USA 2000;97 (3):1269-1274 [PubMed]

Hazenberg MD, Hamann D, Schuitemaker H, Miedema F, T cell depletion in HIV-1 infection: how CD4+ T cells go out of stock. NAT IMMUNOL 2000;1 (4):285-289 [PubMed]

Kootstra NA, Zwart BM, Schuitemaker H, Diminished human immunodeficiency virus type 1 reverse transcription and nuclear transport in primary macrophages arrested in early G(1) phase of the cell cycle. J VIROL 2000;74 (4):1712-1717 [PubMed]

Kostense S, Krop E, Blaak H, Schuitemaker H, Miedema F, Normalization of the CD4 T cell receptor repertoire after evolution of syncytium-inducing HIV-1 variants. AIDS 2000;14 (3):330-331 [PubMed]

Maas JJ, Gange SJ, Schuitemaker H, Coutinho RA, van Leeuwen R, Margolick JB, Strong association between failure of T cell homeostasis and the syncytium-inducing phenotype among HIV-1-infected men in the Amsterdam Cohort Study. AIDS 2000;14 (9):1155-1161 [PubMed]

Putter H, Prins JM, Jurriaans S, Roos M, Ferguson NM, van Praag R, van der Hoek L, Schuitemaker H, Anderson RM, Goudsmit J, Lange JM, de Wolf F, Slower decline of plasma HIV-1 RNA following highly suppressive antiretroviral therapy in primary compared with chronic infection. AIDS 2000;14 (18):2831-2839 [PubMed]

Reijers MH, Weigel HM, Hart AA, ten Kate RW, Mulder JW, Reiss P, Schuitemaker H, Hoetelmans RM, Weverling GJ, Lange JM, Toxicity and drug exposure in a quadruple drug regimen in HIV-1 infected patients participating in the ADAM study. AIDS 2000;14 (1):59-67 [PubMed]

Schuitemaker H, Miedema F, editors, AIDS pathogenesis. Amsterdam: Kluwer; 2000. 294p. ISBN 9780792361961

Scoggins RM, Taylor JR Jr, Patrie J, van't Wout AB, Schuitemaker H, Camerini D, Pathogenesis of primary R5 human immunodeficiency virus type 1 clones in SCID-hu mice. J VIROL 2000;74 (7):3205-3216 [PubMed]

van Rij RP, Blaak H, Visser JA, Brouwer M, Rientsma R, Broersen S, de Roda Husman AM, Schuitemaker H, Differential coreceptor expression allows for independent evolution of non-syncytium-inducing and syncytium-inducing HIV-1. J CLIN INVEST 2000;106 (8):1039-1052 [PubMed]

Abebe A, Demissie D, Goudsmit J, Brouwer M, Kuiken CL, Pollakis G, Schuitemaker H, Fontanet AL, Rinke de Wit TF, HIV-1 subtype C syncytium- and non-syncytium-inducing phenotypes and coreceptor usage among Ethiopian patients with AIDS. AIDS 1999;13 (11):1305-1311 [PubMed]

Berkowitz RD, van't Wout AB, Kootstra NA, Moreno ME, Linquist-Stepps VD, Bare C, Stoddart CA, Schuitemaker H, McCune JM, R5 strains of human immunodeficiency virus type 1 from rapid progressors lacking X4 strains do not possess X4-type pathogenicity in human thymus. J VIROL 1999;73 (9):7817-7822 [PubMed]

de Roda Husman AM, Blaak H, Brouwer M, Schuitemaker H, CC chemokine receptor 5 cell-surface expression in relation to CC chemokine receptor 5 genotype and the clinical course of HIV-1 infection. J IMMUNOL 1999;163 (8):4597-4603 [PubMed]

de Roda Husman AM, van Rij RP, Blaak H, Broersen S, Schuitemaker H, Adaptation to promiscuous usage of chemokine receptors is not a prerequisite for human immunodeficiency virus type 1 disease progression. J INFECT DIS 1999;180 (4):1106-1115 [PubMed]

Koot M, van Leeuwen R, de Goede RE, Keet IP, Danner S, Eeftinck Schattenkerk JK, Reiss P, Tersmette M, Lange JM, Schuitemaker H, Conversion rate towards a syncytium-inducing (SI) phenotype during different stages of human immunodeficiency virus type 1 infection and prognostic value of SI phenotype for survival after AIDS diagnosis. J INFECT DIS 1999;179 (1):254-258 [PubMed]

Kootstra NA, Schuitemaker H, Phenotype of HIV-1 lacking a functional nuclear localization signal in matrix protein of gag and Vpr is comparable to wild-type HIV-1 in primary macrophages. VIROLOGY 1999;253 (2):170-180 [PubMed]

Meyer L, Magierowska M, Hubert JB, Theodorou I, van Rij R, Prins M, de Roda Husman AM, Coutinho R, Schuitemaker H, CC-chemokine receptor variants, SDF-1 polymorphism, and disease progression in 720 HIV-infected patients. SEROCO Cohort. Amsterdam Cohort Studies on AIDS. AIDS 1999;13 (5):624-626 [PubMed]

Prins JM, Jurriaans S, van Praag RM, Blaak H, van Rij R, Schellekens PT, ten Berge IJ, Yong SL, Fox CH, Roos MT, de Wolf F, Goudsmit J, Schuitemaker H, Lange JM, Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy. AIDS 1999;13 (17):2405-2410 [PubMed]

Schinkel J, Langendam MW, Coutinho RA, Krol A, Brouwer M, Schuitemaker H, No evidence for an effect of the CCR5 delta32/+ and CCR2b 64I/+ mutations on human immunodeficiency virus (HIV)-1 disease progression among HIV-1-infected injecting drug users. J INFECT DIS 1999;179 (4):825-831 [PubMed]

van Rij RP, Portegies P, Hallaby T, Lange JM, Visser J, de Roda Husman AM, van 't Wout AB, Schuitemaker H, Reduced prevalence of the CCR5 delta32 heterozygous genotype in human immunodeficiency virus-infected individuals with AIDS dementia complex. J INFECT DIS 1999;180 (3):854-857 [PubMed]

Berger EA, Doms RW, Fenyö EM, Korber BT, Littman DR, Moore JP, Sattentau QJ, Schuitemaker H, Sodroski J, Weiss RA, A new classification for HIV-1. NATURE 1998;391 (6664):240 [PubMed]

Blaak H, Brouwer M, Ran LJ, de Wolf F, Schuitemaker H, In vitro replication kinetics of human immunodeficiency virus type 1 (HIV-1) variants in relation to virus load in long-term survivors of HIV-1 infection. J INFECT DIS 1998;177 (3):600-610 [PubMed]

Blaak H, van't Wout AB, Brouwer M, Cornelissen M, Kootstra NA, Albrecht-van Lent N, Keet RP, Goudsmit J, Coutinho RA, Schuitemaker H, Infectious cellular load in human immunodeficiency virus type 1 (HIV-1)-infected individuals and susceptibility of peripheral blood mononuclear cells from their exposed partners to non-syncytium-inducing HIV-1 as major determinants for HIV-1 transmission in homosexual couples. J VIROL 1998;72 (1):218-224 [PubMed]

Bogers WM, Koornstra WH, Dubbes RH, ten Haaft PJ, Verstrepen BE, Jhagjhoorsingh SS, Haaksma AG, Niphuis H, Laman JD, Norley S, Schuitemaker H, Goudsmit J, Hunsmann G, Heeney JL, Wigzell H, Characteristics of primary infection of a European human immunodeficiency virus type 1 clade B isolate in chimpanzees. J GEN VIROL 1998;79 ( Pt 12):2895-2903 [PubMed]

Bos OJ, Sunyé DG, Nieuweboer CE, van Engelenburg FA, Schuitemaker H, Over J, Virus validation of pH 4-treated human immunoglobulin products produced by the Cohn fractionation process. BIOLOGICALS 1998;26 (4):267-276 [PubMed]

de Roda Husman AM, Schuitemaker H, Chemokine receptors and the clinical course of HIV-1 infection. TRENDS MICROBIOL 1998;6 (6):244-249 [PubMed]

Hoetelmans RM, Reijers MH, Weverling GJ, ten Kate RW, Wit FW, Mulder JW, Weigel HM, Frissen PH, Roos M, Jurriaans S, Schuitemaker H, de Wolf F, Beijnen JH, Lange JM, The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy. AIDS 1998;12 (11):F111-F115 [PubMed]

Kootstra NA, Schuitemaker H, Proliferation-dependent replication in primary macrophages of macrophage-tropic HIV type 1 variants. AIDS RES HUM RETROV 1998;14 (4):339-345 [PubMed]

Maas J, de Roda Husman AM, Brouwer M, Krol A, Coutinho R, Keet I, van Leeuwen R, Schuitemaker H, Presence of the variant mannose-binding lectin alleles associated with slower progression to AIDS. Amsterdam Cohort Study. AIDS 1998;12 (17):2275-2280 [PubMed]

Pontesilli O, Klein MR, Kerkhof-Garde SR, Pakker NG, de Wolf F, Schuitemaker H, Miedema F, Longitudinal analysis of human immunodeficiency virus type 1-specific cytotoxic T lymphocyte responses: a predominant gag-specific response is associated with nonprogressive infection. J INFECT DIS 1998;178 (4):1008-1018 [PubMed]

Reijers MH, Weverling GJ, Jurriaans S, Wit FW, van Leeuwen R, Bruisten SM, Frissen PH, Weigel HM, Mulder JW, ten Kate RW, de Wolf F, Schuitemaker H, Lange JM, Amsterdam duur van antiretrovirale therapie (ADAM)--onderzoek: inductie-onderhoudsbehandeling bij HIV-I-infectie, preliminaire resultaten. NED TIJDSCHR GENEESKD 1998;142 (40):2230 [PubMed]

Reijers MH, Weverling GJ, Jurriaans S, Wit FW, Weigel HM, ten Kate RW, Mulder JW, Frissen PH, van Leeuwen R, Reiss P, Schuitemaker H, de Wolf F, Lange JM, Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) study. LANCET 1998;352 (9123):185-190 [PubMed]

Spijkerman I, de Wolf F, Langendam M, Schuitemaker H, Coutinho R, Emergence of syncytium-inducing human immunodeficiency virus type 1 variants coincides with a transient increase in viral RNA level and is an independent predictor for progression to AIDS. J INFECT DIS 1998;178 (2):397-403 [PubMed]

van Rij RP, Broersen S, Goudsmit J, Coutinho RA, Schuitemaker H, The role of a stromal cell-derived factor-1 chemokine gene variant in the clinical course of HIV-1 infection. AIDS 1998;12 (9):F85-F90 [PubMed]

van Rij RP, de Roda Husman AM, Brouwer M, Goudsmit J, Coutinho RA, Schuitemaker H, Role of CCR2 genotype in the clinical course of syncytium-inducing (SI) or non-SI human immunodeficiency virus type 1 infection and in the time to conversion to SI virus variants. J INFECT DIS 1998;178 (6):1806-1811 [PubMed]

van 't Wout AB, Blaak H, Ran LJ, Brouwer M, Kuiken C, Schuitemaker H, Evolution of syncytium-inducing and non-syncytium-inducing biological virus clones in relation to replication kinetics during the course of human immunodeficiency virus type 1 infection. J VIROL 1998;72 (6):5099-5107 [PubMed]

van't Wout AB, Ran LJ, Kuiken CL, Kootstra NA, Pals ST, Schuitemaker H, Analysis of the temporal relationship between human immunodeficiency virus type 1 quasispecies in sequential blood samples and various organs obtained at autopsy. J VIROL 1998;72 (1):488-496 [PubMed]

van 't Wout AB, Ran LJ, Nijhuis M, Tijnagel JM, de Groot T, van Leeuwen R, Boucher CA, Schuitemaker H, Schuurman R, Efficient inhibition of both syncytium-inducing and non-syncytium-inducing wild-type HIV-1 by lamivudine in vivo. AIDS 1998;12 (10):1169-1176 [PubMed]

Weverling GJ, Lange JM, Jurriaans S, Prins JM, Lukashov VV, Notermans DW, Roos M, Schuitemaker H, Hoetelmans RM, Danner SA, Goudsmit J, de Wolf F, Alternative multidrug regimen provides improved suppression of HIV-1 replication over triple therapy. AIDS 1998;12 (11):F117-F122 [PubMed]

Wolthers KC, Schuitemaker H, Miedema F, Rapid CD4+ T-cell turnover in HIV-1 infection: a paradigm revisited. IMMUNOL TODAY 1998;19 (1):44-48 [PubMed]

Blaak H, de Wolf F, van 't Wout AB, Pakker NG, Bakker M, Goudsmit J, Schuitemaker H, Temporal relationship between human immunodeficiency virus type 1 RNA levels in serum and cellular infectious load in peripheral blood. J INFECT DIS 1997;176 (5):1383-1387 [PubMed]

de Roda Husman AM, Koot M, Cornelissen M, Keet IP, Brouwer M, Broersen SM, Bakker M, Roos MT, Prins M, de Wolf F, Coutinho RA, Miedema F, Goudsmit J, Schuitemaker H, Association between CCR5 genotype and the clinical course of HIV-1 infection. ANN INTERN MED 1997;127 (10):882-890 [PubMed]

Groenink M, Swart PJ, Broersen S, Kuipers M, Meijer DK, Schuitemaker H, Potent inhibition of replication of primary HIV type 1 isolates in peripheral blood lymphocytes by negatively charged human serum albumins. AIDS RES HUM RETROV 1997;13 (2):179-185 [PubMed]

Koot M, van 't Wout AB, Miedema F, Schuitemaker H, Use of Immunological and Viral Parameters to Predict Progression of HIV Infection During Natural Course and Antiretroviral Treatment. BIODRUGS 1997;8 (4):243-249 [PubMed]

Kootstra NA, Miedema F, Schuitemaker H, Analysis of CD8+ T lymphocyte-mediated nonlytic suppression of autologous and heterologous primary human immunodeficiency virus type 1 isolates. AIDS RES HUM RETROV 1997;13 (8):685-693 [PubMed]

Pontesilli O, Klein MR, Kerkhof-Garde SR, Pakker NG, de Wolf F, Schuitemaker H, Miedema F, Kinetics of immune functions and virus replication during HIV-1 infection. IMMUNOL LETT 1997;57 (1-3):125-130 [PubMed]

van't Wout AB, Ran LJ, de Jong MD, Bakker M, van Leeuwen R, Notermans DW, Loeliger AE, de Wolf F, Danner SA, Reiss P, Boucher CA, Lange JM, Schuitemaker H, Selective inhibition of syncytium-inducing and nonsyncytium-inducing HIV-1 variants in individuals receiving didanosine or zidovudine, respectively. J CLIN INVEST 1997;100 (9):2325-2332 [PubMed]

Fouchier RA, Meyaard L, Brouwer M, Hovenkamp E, Schuitemaker H, Broader tropism and higher cytopathicity for CD4+ T cells of a syncytium-inducing compared to a non-syncytium-inducing HIV-1 isolate as a mechanism for accelerated CD4+ T cell decline in vivo. VIROLOGY 1996;219 (1):87-95 [PubMed]

Fouchier RA, Schuitemaker H, Molecular determinants of human immunodeficiency virus type I phenotype variability. EUR J CLIN INVEST 1996;26 (3):175-185 [PubMed]

Koot M, van 't Wout AB, Kootstra NA, de Goede RE, Tersmette M, Schuitemaker H, Relation between changes in cellular load, evolution of viral phenotype, and the clonal composition of virus populations in the course of human immunodeficiency virus type 1 infection. J INFECT DIS 1996;173 (2):349-354 [PubMed]

Kuipers ME, Huisman JG, Swart PJ, de Béthune MP, Pauwels R, Schuitemaker H, de Clercq E, Meijer DK, Mechanism of anti-HIV activity of negatively charged albumins: biomolecular interaction with the HIV-1 envelope protein gp120. J ACQUIR IMMUNE DEFIC SYNDR HUM RETROVIROL 1996;11 (5):419-429 [PubMed]

Schuitemaker H, Miedema F, Viral and cellular determinants of HIV-1 replication in macrophages. AIDS 1996;10 (Suppl. A):S25-S32 [PubMed]

Swart PJ, Beljaars E, Smit C, Pasma A, Schuitemaker H, Meijer DK, Comparative pharmacokinetic, immunologic and hematologic studies on the anti-HIV-1/2 compounds aconitylated and succinylated HSA. J DRUG TARGET 1996;4 (2):109-116 [PubMed]

van 't Wout AB, de Jong MD, Kootstra NA, Veenstra J, Lange JM, Boucher CA, Schuitemaker H, Changes in cellular virus load and zidovudine resistance of syncytium-inducing and non-syncytium-inducing human immunodeficiency virus populations under zidovudine pressure: a clonal analysis. J INFECT DIS 1996;174 (4):845-849 [PubMed]

Fouchier RA, Broersen SM, Brouwer M, Tersmette M, van't Wout AB, Groenink M, Schuitemaker H, Temporal relationship between elongation of the HIV type 1 glycoprotein 120 V2 domain and the conversion toward a syncytium-inducing phenotype. AIDS RES HUM RETROV 1995;11 (12):1473-1478 [PubMed]

Fouchier RA, Brouwer M, Broersen SM, Schuitemaker H, Simple determination of human immunodeficiency virus type 1 syncytium-inducing V3 genotype by PCR. J CLIN MICROBIOL 1995;33 (4):906-911 [PubMed]

Groenink M, Moore JP, Broersen S, Schuitemaker H, Equal levels of gp120 retention and neutralization resistance of phenotypically distinct primary human immunodeficiency virus type 1 variants upon soluble CD4 treatment. J VIROL 1995;69 (1):523-527 [PubMed]

Guillon C, Bedin F, Fouchier RA, Schuitemaker H, Gruters RA, Completion of nucleotide sequences of non-syncytium-inducing and syncytium-inducing HIV type 1 variants isolated from the same patient. AIDS RES HUM RETROV 1995;11 (12):1537-1541 [PubMed]

Klein MR, van Baalen CA, Holwerda AM, Kerkhof Garde SR, Bende RJ, Keet IP, Eeftinck-Schattenkerk JK, Osterhaus AD, Schuitemaker H, Miedema F, Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics. J EXP MED 1995;181 (4):1365-1372 [PubMed]

Schuitemaker H, Fouchier RA, Broersen S, Groenink M, Koot M, van 't Wout AB, Huisman HG, Tersmette M, Miedema F, Envelope V2 configuration and HIV-1 phenotype: clarification. SCIENCE 1995;268 (5207):115 [PubMed]

Schuitemaker H, Miedema F, Comment on Mosier and Sieburg. IMMUNOL TODAY 1995;16 (1):50-52 [PubMed]

Veenstra J, Schuurman R, Cornelissen M, van't Wout AB, Boucher CA, Schuitemaker H, Goudsmit J, Coutinho RA, Transmission of zidovudine-resistant human immunodeficiency virus type 1 variants following deliberate injection of blood from a patient with AIDS: characteristics and natural history of the virus. CLIN INFECT DIS 1995;21 (3):556-560 [PubMed]

Wrin T, Loh TP, Vennari JC, Schuitemaker H, Nunberg JH, Adaptation to persistent growth in the H9 cell line renders a primary isolate of human immunodeficiency virus type 1 sensitive to neutralization by vaccine sera. J VIROL 1995;69 (1):39-48 [PubMed]

Fouchier RA, Brouwer M, Kootstra NA, Huisman HG, Schuitemaker H, HIV-1 macrophage tropism is determined at multiple levels of the viral replication cycle. J CLIN INVEST 1994;94 (5):1806-1814 [PubMed]

Jurriaans S, van Gemen B, Weverling GJ, van Strijp D, Nara P, Coutinho R, Koot M, Schuitemaker H, Goudsmit J, The natural history of HIV-1 infection: virus load and virus phenotype independent determinants of clinical course?. VIROLOGY 1994;204 (1):223-233 [PubMed]

Kootstra NA, van 't Wout A, Huisman HG, Miedema F, Schuitemaker H, Interference of interleukin-10 with human immunodeficiency virus type 1 replication in primary monocyte-derived macrophages. J VIROL 1994;68 (11):6967-6975 [PubMed]

Roos MT, de Leeuw NA, Claessen FA, Huisman HG, Kootstra NA, Meyaard L, Schellekens PT, Schuitemaker H, Miedema F, Viro-immunological studies in acute HIV-1 infection. AIDS 1994;8 (11):1533-1538 [PubMed]

Schuitemaker H, IL4 and IL10 as potent inhibitors of HIV1 replication in macrophages in vitro: a role for cytokines in the in vivo virus host range?. RES IMMUNOL 1994;145 (8-9):588-92; discussion 592-4 [PubMed]

Schuitemaker H, Macrophage-tropic HIV-1 variants: initiators of infection and AIDS pathogenesis?. J LEUKOCYTE BIOL 1994;56 (3):218-224 [PubMed]

Schuitemaker H, Koot M, Miedema F, Recent development on research in AIDS pathogenesis. VOX SANG 1994;67 (Suppl. 3):133-136 [PubMed]

Schuitemaker H, Kootstra NA, Fouchier RA, Hooibrink B, Miedema F, Productive HIV-1 infection of macrophages restricted to the cell fraction with proliferative capacity. EMBO J 1994;13 (24):5929-5936 [PubMed]

van't Wout AB, Kootstra NA, Mulder-Kampinga GA, Albrecht-van Lent N, Scherpbier HJ, Veenstra J, Boer K, Coutinho RA, Miedema F, Schuitemaker H, Macrophage-tropic variants initiate human immunodeficiency virus type 1 infection after sexual, parenteral, and vertical transmission. J CLIN INVEST 1994;94 (5):2060-2067 [PubMed]

Groenink M, Fouchier RA, Broersen S, Baker CH, Koot M, van't Wout AB, Huisman HG, Miedema F, Tersmette M, Schuitemaker H, Relation of phenotype evolution of HIV-1 to envelope V2 configuration. SCIENCE 1993;260 (5113):1513-1516 [PubMed]

Meyaard L, Schuitemaker H, Miedema F, T-cell dysfunction in HIV infection: anergy due to defective antigen-presenting cell function?. IMMUNOL TODAY 1993;14 (4):161-164 [PubMed]

Schuitemaker H, Groenink M, Meyaard L, Kootstra NA, Fouchier RA, Gruters RA, Huisman HG, Tersmette M, Miedema F, Early replication steps but not cell type-specific signalling of the viral long terminal repeat determine HIV-1 monocytotropism. AIDS RES HUM RETROV 1993;9 (7):669-675 [PubMed]

Schuitemaker H, Groenink M, Tersmette M, Miedema F, HIV tropism. NATURE 1993;361 (6410):310 [PubMed]

Schuitemaker H, Meyaard L, Kootstra NA, Dubbes R, Otto SA, Tersmette M, Heeney JL, Miedema F, Lack of T cell dysfunction and programmed cell death in human immunodeficiency virus type 1-infected chimpanzees correlates with absence of monocytotropic variants. J INFECT DIS 1993;168 (5):1140-1147 [PubMed]

Tersmette M, Schuitemaker H, Virulent HIV strains?. AIDS 1993;7 (8):1123-1125 [PubMed]

Fouchier RA, Groenink M, Kootstra NA, Tersmette M, Huisman HG, Miedema F, Schuitemaker H, Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J VIROL 1992;66 (5):3183-3187 [PubMed]

Groenink M, Andeweg AC, Fouchier RA, Broersen S, van der Jagt RC, Schuitemaker H, de Goede RE, Bosch ML, Huisman HG, Tersmette M, Phenotype-associated env gene variation among eight related human immunodeficiency virus type 1 clones: evidence for in vivo recombination and determinants of cytotropism outside the V3 domain. J VIROL 1992;66 (10):6175-6180 [PubMed]

Meyaard L, Otto SA, Schuitemaker H, Miedema F, Effects of HIV-1 Tat protein on human T cell proliferation. EUR J IMMUNOL 1992;22 (10):2729-2732 [PubMed]

Schuitemaker H, Koot M, Kootstra NA, Dercksen MW, de Goede RE, van Steenwijk RP, Lange JM, Schattenkerk JK, Miedema F, Tersmette M, Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population. J VIROL 1992;66 (3):1354-1360 [PubMed]

Schuitemaker H, Kootstra NA, Groenink M, de Goede RE, Miedema F, Tersmette M, Differential tropism of clinical HIV-1 isolates for primary monocytes and promonocytic cell lines. AIDS RES HUM RETROV 1992;8 (9):1679-1682 [PubMed]

Schuitemaker H, Kootstra NA, Koppelman MH, Bruisten SM, Huisman HG, Tersmette M, Miedema F, Proliferation-dependent HIV-1 infection of monocytes occurs during differentiation into macrophages. J CLIN INVEST 1992;89 (4):1154-1160 [PubMed]

Schuitemaker H, Kootstra NA, de Goede RE, de Wolf F, Miedema F, Tersmette M, Monocytotropic human immunodeficiency virus type 1 (HIV-1) variants detectable in all stages of HIV-1 infection lack T-cell line tropism and syncytium-inducing ability in primary T-cell culture. J VIROL 1991;65 (1):356-363 [PubMed]

Schuitemaker H, Kootstra NA, van Oers MH, van Lambalgen R, Tersmette M, Miedema F, Induction of monocyte proliferation and HIV expression by IL-3 does not interfere with anti-viral activity of zidovudine. BLOOD 1990;76 (8):1490-1493 [PubMed]

Kuppen PJ, Schuitemaker H, van 't Veer LJ, de Bruijn EA, van Oosterom AT, Schrier PI, cis-diamminedichloroplatinum(II)-resistant sublines derived from two human ovarian tumor cell lines. CANCER RES 1988;48 (12):3355-3359 [PubMed]